DirectCaseReview.com Launches an Online Platform to Help Car Accident Victims Learn What Their Case May Be Worth 2026-10-25 · EIN Presswire · SaaS, Automotive, Legal, Internet & apps https://www.einpresswire.com/article/951551194/directcasereview-com-launches-an-online-platform-to-help-car-accident-victims-learn-what-their-case-may-be-worth Direct Case Review Matches Clients with Attorneys A free platform connecting people injured in motor vehicle accidents with local personal injury attorneys for a no-cost, no-obligation case review. SCOTTSDALE, AZ, UNITED STATES, October 25, 2026 / EINPresswire.com / -- Today, DirectCaseReview.com announced the launch of its online platform that connects people injured in motor vehicle accidents with experienced local ———————————————————————————————————————————————————————————— Flotek Deadline: FTK Investors Have Opportunity to Lead Flotek Industries, Inc. Securities Fraud Lawsuit 2026-10-25 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/flotek-deadline-ftk-investors-have-opportunity-to-lead-flotek-industries-inc-securities-fraud-lawsuit-302918565.html NEW YORK, Oct. 24, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Flotek Industries, Inc. (NYSE: FTK) between August 3, 2026 and August 17, 2026, both dates inclusive (the "Class Period"), of the important October 26, 2026 lead... ———————————————————————————————————————————————————————————— HYLN Deadline: HYLN Investors Have Opportunity to Lead Hyliion Holdings Corp. Securities Fraud Lawsuit 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/hyln-deadline-hyln-investors-have-opportunity-to-lead-hyliion-holdings-corp-securities-fraud-lawsuit-302918546.html NEW YORK, Oct. 24, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hyliion Holdings Corp. (NYSE American: HYLN) between May 12, 2026 and June 23, 2026, both dates inclusive (the "Class Period"), of the important October 27,... ———————————————————————————————————————————————————————————— GIL Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Gildan Activewear Inc. Class Action Lawsuit 2026-10-24 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/24/3387710/32719/en/gil-class-action-reminder-robbins-llp-reminds-investors-of-the-lead-plaintiff-deadline-in-the-gildan-activewear-inc-class-action-lawsuit.html Robbins LLP is investigating allegations that Gildan Activewear failed to disclose that it had inadequate internal controls and was channel stuffing. ———————————————————————————————————————————————————————————— NCPL Investors Have Opportunity to Lead Netcapital Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/ncpl-investors-have-opportunity-to-lead-netcapital-inc-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302917697.html NEW YORK, Oct. 24, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Netcapital Inc. (NASDAQ: NCPL) between December 15, 2021 and September 3, 2026, both dates inclusive (the "Class Period"), of the important December 7, 2026... ———————————————————————————————————————————————————————————— FuelCell Energy, Inc. Class Action Reminder – Robbins LLP Encourages FCEL Investors to Contact the Firm for Information About Their Rights 2026-10-24 · GlobeNewswire · Energy, Industrial, Legal https://www.globenewswire.com/news-release/2026/10/24/3387709/32719/en/fuelcell-energy-inc-class-action-reminder-robbins-llp-encourages-fcel-investors-to-contact-the-firm-for-information-about-their-rights.html Robbins LLP is investigating allegations that FuelCell Energy Inc. misled investors regarding its manufacturing capacity. ———————————————————————————————————————————————————————————— UNCY DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY 2026-10-24 · GlobeNewswire · Finance, Biotech & pharma, Legal https://www.globenewswire.com/news-release/2026/10/24/3387708/673/en/uncy-deadline-notice-rosen-a-highly-recognized-law-firm-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-november-2-deadline-in-securities-class-a.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Baidu, Inc. Class Action Reminder – Robbins LLP Encourages BIDU Investors to Contact the Firm for Information About Their Rights 2026-10-24 · GlobeNewswire · AI, Legal, Marketing & advertising, Internet & apps https://www.globenewswire.com/news-release/2026/10/24/3387707/32719/en/baidu-inc-class-action-reminder-robbins-llp-encourages-bidu-investors-to-contact-the-firm-for-information-about-their-rights.html Baidu, Inc. (BIDU) faces allegations it overstated the ability of its AI business to mitigate rapid declines in its legacy online marketing business. ———————————————————————————————————————————————————————————— AST SpaceMobile, Inc. Class Action Reminder - Robbins LLP Encourages ASTS Investors to Contact the Firm for Information About Their Rights 2026-10-24 · GlobeNewswire · Aerospace & defense, Legal https://www.globenewswire.com/news-release/2026/10/24/3387706/32719/en/ast-spacemobile-inc-class-action-reminder-robbins-llp-encourages-asts-investors-to-contact-the-firm-for-information-about-their-rights.html AST SpaceMobile, Inc. faces allegations that it misled investors regarding its competitive position in the satellite D2C market. ———————————————————————————————————————————————————————————— YSS DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages York Space Systems Inc. Investors to Secure Counsel Before Important October 30 Deadline in Securities Class Action – YSS 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387704/673/en/yss-deadline-notice-rosen-a-leading-national-firm-encourages-york-space-systems-inc-investors-to-secure-counsel-before-important-october-30-deadline-in-securities-class-action-yss.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of York Space Systems Inc. (NYSE: YSS): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with York Space Systems’ January 2026 initial public offering (“IPO”); and/or (ii) securities between January 29, 2026 and May 11, 2026, both dates inclusive (the “Class Period”), of the important October 30, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Siegal & Richardson Announces Civil Rights Lawsuit Filed Against Historic Marin County Bar 2026-10-24 · PRWeb · Legal https://www.prweb.com/releases/siegal--richardson-announces-civil-rights-lawsuit-filed-against-historic-marin-county-bar-302917771.html Lawsuit brought on behalf of longtime Northern California entrepreneur and GCX founder John Kruger raises questions about equal access to public businesses under California law. LARKSPUR, Calif., Oct. 24, 2026 -- Siegal & Richardson, a Berkeley-based law firm, announces... ———————————————————————————————————————————————————————————— PZZA DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Papa John’s International, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - PZZA 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387703/673/en/pzza-deadline-notice-rosen-leading-trial-attorneys-encourages-papa-john-s-international-inc-investors-to-secure-counsel-before-important-november-2-deadline-in-securities-class-act.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Papa John’s International, Inc. (NASDAQ: PZZA) between August 7, 2025 and August 5, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— INV Deadline: INV Investors Have Opportunity to Lead Innventure, Inc. Securities Fraud Lawsuit 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/inv-deadline-inv-investors-have-opportunity-to-lead-innventure-inc-securities-fraud-lawsuit-302918564.html NEW YORK, Oct. 24, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Innventure, Inc. (NASDAQ: INV) between November 17, 2025 and August 13, 2026, both dates inclusive (the "Class Period"), of the important October 27, 2026 lead... ———————————————————————————————————————————————————————————— BBNX DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387702/673/en/bbnx-deadline-alert-rosen-a-leading-law-firm-encourages-beta-bionics-inc-investors-to-secure-counsel-before-important-november-3-deadline-in-securities-class-action-bbnx.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the “Class Period”), of the important November 3, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Rosen Law Firm Encourages Yiren Digital Ltd. Investors to Inquire About Securities Class Action Investigation - YRD 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-yiren-digital-ltd-investors-to-inquire-about-securities-class-action-investigation---yrd-302917707.html NEW YORK, Oct. 24, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Yiren Digital Ltd. (NYSE: YRD) resulting from allegations that Yiren may have issued materially misleading... ———————————————————————————————————————————————————————————— THE RAIMONDO LAW FIRM SECURES $325,000 MEDIATION SETTLEMENT FOR HARDWARE STORE CUSTOMER INJURED BY FALLING TOOLBOXES 2026-10-24 · EIN Presswire · Healthcare, Legal, Medical devices https://www.einpresswire.com/article/951843365/the-raimondo-law-firm-secures-325-000-mediation-settlement-for-hardware-store-customer-injured-by-falling-toolboxes Attorney MICHAEL RAIMONDO Attorney DAVID J. RAIMONDO Attorney JON L. RAIMONDO THE CUSTOMER’S NECK INJURIES REQUIRED SURGERY AND PERMANENT MEDICAL IMPLANTS AFTER RETAILER FAILED TO KEEP OVERHEAD MERCHANDISE SECURE When choices and negligence result in a severe injury, surgery, and permanent hardware, we fight for the compensation that the victim is owed.” — Michael A. Raimondo, Esq. LAKE GROVE, NY, UNITED STATES, Octo ———————————————————————————————————————————————————————————— BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/bbnx-deadline-bbnx-investors-have-opportunity-to-lead-beta-bionics-inc-securities-fraud-lawsuit-302918530.html NEW YORK, Oct. 24, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026... ———————————————————————————————————————————————————————————— ASTS Deadline in 20 Days: AST SpaceMobile, Inc Class Action Lawsuit: Investors Face November 13, 2026, Deadline - Kessler Topaz Meltzer & Check, LLP 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/asts-deadline-in-20-days-ast-spacemobile-inc-class-action-lawsuit-investors-face-november-13-2026-deadline---kessler-topaz-meltzer--check-llp-302917693.html Did you buy ASTS securities between March 4, 2025 and July 15, 2026? Affected ASTS Investor Summary Who: AST SpaceMobile, Inc. (NASDAQ: ASTS) What: Securities fraud class action lawsuit filed Class Period: March 4, 2025 through July 15, 2026 Deadline to Seek Lead Plaintiff Status:... ———————————————————————————————————————————————————————————— T. Madden & Associates, P.C.: Georgia Motorcycle Accident Lawyer Shares Safety Reminders for National Motorcycle Ride Day 2026-10-24 · PR Now · Legal https://pressreleasenews.org/pressroom/t-madden-associates-p-c-georgia-motorcycle-accident-lawyer-shares-safety-reminders-for-national-motorcycle-ride-day As National Motorcycle Ride Day marks the fall riding season, T. Madden & Associates, P.C. is sharing practical safety tips for both motorcyclists and the drivers who share the road with them. ———————————————————————————————————————————————————————————— AppLovin Corporation (APP) Class Action Lawsuit: Investors Face November 16, 2026, Deadline - Kessler Topaz Meltzer & Check, LLP 2026-10-24 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/24/3387692/0/en/applovin-corporation-app-class-action-lawsuit-investors-face-november-16-2026-deadline-kessler-topaz-meltzer-check-llp.html Did you buy APP securities between February 12, 2026 and August 5, 2026? ———————————————————————————————————————————————————————————— Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit 2026-10-24 · PR Newswire · Finance, Biotech & pharma, Legal https://www.prnewswire.com/news-releases/unicycive-deadline-uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302918542.html NEW YORK, Oct. 24, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November... ———————————————————————————————————————————————————————————— INNVENTURE DEADLINE OCTOBER 27th: Bragar Eagel & Squire, P.C. Urges Innventure, Inc. Investors to Contact the Firm Before the October 27th Lead Plaintiff Deadline 2026-10-24 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/24/3387690/0/en/innventure-deadline-october-27th-bragar-eagel-squire-p-c-urges-innventure-inc-investors-to-contact-the-firm-before-the-october-27th-lead-plaintiff-deadline.html Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Innventure (INV) To Contact Him Directly To Discuss Their Options ———————————————————————————————————————————————————————————— XTIA URGENT DEADLINE: Bragar Eagel & Squire, P.C. Urges XTI Aerospace, Inc. Investors to Contact the Firm Regarding Their Rights Before October 27th 2026-10-24 · GlobeNewswire · Aerospace & defense, Legal https://www.globenewswire.com/news-release/2026/10/24/3387686/0/en/xtia-urgent-deadline-bragar-eagel-squire-p-c-urges-xti-aerospace-inc-investors-to-contact-the-firm-regarding-their-rights-before-october-27th.html Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In XTI (XTIA) To Contact Him Directly To Discuss Their Options ———————————————————————————————————————————————————————————— HYLN DEADLINE TUESDAY: Hyliion Holdings Corp. Investors Have Until October 27th to Seek Lead Plaintiff Role with Bragar Eagel & Squire, P.C. 2026-10-24 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/24/3387685/0/en/hyln-deadline-tuesday-hyliion-holdings-corp-investors-have-until-october-27th-to-seek-lead-plaintiff-role-with-bragar-eagel-squire-p-c.html Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hyliion (HYLN) To Contact Him Directly To Discuss Their Options ———————————————————————————————————————————————————————————— Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Darden Restaurants, Inc. for Alleged Failure to Reimburse Employees' Business Expenses 2026-10-24 · PR Newswire · Food & drink, Legal https://www.prnewswire.com/news-releases/employment-law-attorneys-at-blumenthal-nordrehaug-bhowmik-de-blouw-llp-filed-a-lawsuit-against-darden-restaurants-inc-for-alleged-failure-to-reimburse-employees-business-expenses-302917695.html Darden Restaurants, Inc., owner and operator of full-service dining chains, allegedly failed to reimburse employees for their business expenses incurred while performing the job as instructed by Defendant. This resulted in inaccurate wage statements amongst other allegations. **THIS IS AN... ———————————————————————————————————————————————————————————— McIntosh Lawyers Strengthens Its Approach to Complex Financial Issues in Divorce 2026-10-24 · ACCESS Newswire · Finance, Real estate, Legal, Consumer electronics https://finance.yahoo.com/small-business/articles/mcintosh-lawyers-strengthens-approach-complex-123500824.html MEDIA, PA / October 24, 2026 / McIntosh Lawyers, PC is strengthening its approach to complex financial issues arising during divorce, with a continued focus on helping clients understand and address property division, asset valuation, marital debts, business interests, retirement accounts, and other financial considerations that can affect divorce proceedings. Based in Media, Pennsylvania, McIntosh ———————————————————————————————————————————————————————————— The Urbanic Law Firm Strengthens Criminal Defense Representation Across Oklahoma 2026-10-24 · ACCESS Newswire · Biotech & pharma, Legal, Government & policy https://finance.yahoo.com/small-business/articles/urbanic-law-firm-strengthens-criminal-121500588.html OKLAHOMA CITY, OK / October 24, 2026 / The Urbanic Law Firm is strengthening its criminal defense representation across Oklahoma, providing focused legal support to individuals facing criminal allegations in state, federal, and municipal cases. Based in Oklahoma City, the firm represents clients throughout the state in matters involving DUI and DWI, domestic violence, drug offenses, sex crimes, fire ———————————————————————————————————————————————————————————— TYGO Investors Have Opportunity to Lead Tigo Energy, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm 2026-10-24 · PR Newswire · Finance, Energy, Legal https://www.prnewswire.com/news-releases/tygo-investors-have-opportunity-to-lead-tigo-energy-inc-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302917691.html NEW YORK, Oct. 24, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tigo Energy, Inc. (NASDAQ: TYGO) between February 24, 2026 and August 4, 2026, both dates inclusive (the "Class Period"), of the important November 23, 2026 lead... ———————————————————————————————————————————————————————————— BULL Investors Have Opportunity to Lead Webull Corporation Securities Fraud Lawsuit Filed by The Rosen Law Firm 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/bull-investors-have-opportunity-to-lead-webull-corporation-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302917685.html NEW YORK, Oct. 24, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Webull Corporation (NASDAQ: BULL) between April 26, 2025 and October 6, 2026, both dates inclusive (the "Class Period"), of the important December 7, 2026 lead... ———————————————————————————————————————————————————————————— ENSG Investors Have Opportunity to Lead The Ensign Group, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/ensg-investors-have-opportunity-to-lead-the-ensign-group-inc-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302917681.html NEW YORK, Oct. 24, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the "Class Period"), of the important December 7, 2026... ———————————————————————————————————————————————————————————— ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Bank of America Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAC 2026-10-24 · GlobeNewswire · Finance, Banking, Legal https://www.globenewswire.com/news-release/2026/10/24/3387675/673/en/rosen-a-ranked-and-leading-law-firm-encourages-bank-of-america-corporation-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-bac.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Bank of America Corporation (NYSE: BAC) between August 1, 2025 and October 13, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2026. ———————————————————————————————————————————————————————————— ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Lincoln Educational Services Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - LINC 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387674/673/en/rosen-a-ranked-and-leading-law-firm-encourages-lincoln-educational-services-corporation-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-linc.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lincoln Educational Services Corporation (NASDAQ: LINC) between May 11, 2026 and August 9, 2026, inclusive (the “Class Period”), of the important November 10, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QFIN 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387673/673/en/rosen-a-leading-investor-rights-law-firm-encourages-qfin-holdings-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-qfin.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Qfin Holdings, Inc. (NASDAQ: QFIN) between March 18, 2026 and August 25, 2026, inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— ROSEN, THE FIRST FILING FIRM, Encourages Netcapital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NCPL 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387670/673/en/rosen-the-first-filing-firm-encourages-netcapital-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-first-filed-by-the-firm-ncpl.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Netcapital Inc. (NASDAQ: NCPL) between December 15, 2021 and September 3, 2026, both dates inclusive (the “Class Period”), of the important December 7, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. ———————————————————————————————————————————————————————————— ROSEN, THE FIRST FILING FIRM, Encourages Webull Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BULL 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387668/673/en/rosen-the-first-filing-firm-encourages-webull-corporation-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-first-filed-by-the-firm-bull.html NEW YORK, Oct. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Webull Corporation (NASDAQ: BULL) between April 26, 2025 and October 6, 2026, both dates inclusive (the “Class Period”), of the important December 7, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. ———————————————————————————————————————————————————————————— T. Madden & Associates, P.C. Marks Residents' Rights Month by Empowering Local Families to Fight Nursing Home Neglect 2026-10-24 · PR Now · Legal https://pressreleasenews.org/pressroom/t-madden-associates-p-c-marks-residents-rights-month-by-empowering-local-families-to-fight-nursing-home-neglect Jonesboro nursing home neglect lawyer Terance Madden explains Georgia residents’ rights and the warning signs of neglect for Residents’ Rights Month. ———————————————————————————————————————————————————————————— Don't Let Halloween Become a Horror Story: Augusta Personal Injury Lawyer Shares Safety Tips for Trick-or-Treaters, Drivers, and Hosts 2026-10-24 · PR Now · Legal https://pressreleasenews.org/pressroom/dont-let-halloween-become-a-horror-story-augusta-personal-injury-lawyer-shares-safety-tips-for-trick-or-treaters-drivers-and-hosts T. Madden & Associates, P.C. outlines Georgia’s crosswalk and hands-free rules, shares Halloween safety precautions, and explains what to do after a crash or fall. ———————————————————————————————————————————————————————————— Navigating a Changing Market: How AIX Group Is Responding to a Challenging Year 2026-10-24 · Pressat · Real estate, Banking, Legal https://pressat.co.uk/releases/navigating-a-changing-market-how-aix-group-is-responding-to-a-challenging-year-7d73c846fd72443db5f2c9908782abda/ Saturday 24 October, 2026 2026 has been one of the most demanding years in recent memory for financial markets in the Middle East. Instability linked to the ongoing conflict in the region has affected investor confidence, market liquidity and asset valuations, and financial firms across the region are adapting to a changed environment. Pressure from several directions The challenges have come from several sides at once. Currency, commodity and digital-asset markets have become more volatile. Major central banks have followed different policy paths, creating an uncertain interest-rate environment. At the same time, stricter international compliance standards in cross-border banking have lengthened the time it takes for funds to move between markets. Real estate has also slowed. According to property consultancy Cavendish Maxwell, the value of residential sales in Dubai fell 47% year on year in the third quarter of 2026, while the number of transactions fell 38%. S&P Global Ratings estimates that prices fell by 5–15% between the end of 2025 and September 2026. Dubai-based AIX Group is among the firms adjusting to these conditions. According to the company, it continues to operate and to serve its clients, and products that have not been affected by current market conditions continue to operate as usual. One of the AIX product have, however, been affected, through lower valuations, reduced liquidity and longer timelines for realising investments. AIX said it believes that selling assets in the current market would not be in the best interests of its clients, and it has therefore decided to restructure the affected programmes. Clients have been presented with options for the period ahead. The process is being carried out with the support of international law firms, financial advisers and restructuring specialists, and individual steps are subject to the relevant approvals. Keeping clients informed AIX said it understands the concern these conditions create for clients. Updates will be shared with clients directly, and the company will publish all official information exclusively through its official channels. For financial firms across the region, the months ahead will call for careful management through a period of continued uncertainty. ———————————————————————————————————————————————————————————— New York City Trial Attorney Richard M. Kenny Named to Irish America's 2026 Irish Legal 100 2026-10-24 · PRLeap · Legal http://www.prleap.com/pr/314444/new-york-city-trial-attorney-richard-m-kenny-named-to-irish-americas-2026-irish-legal-100 Founder of The Law Offices of Richard M. Kenny honored on Irish America magazine's annual list of Irish-American attorneys and judges. ———————————————————————————————————————————————————————————— ROSEN, A TOP-RANKED AND TRUSTED LAW FIRM, Encourages Duolingo, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DUOL 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387652/673/en/rosen-a-top-ranked-and-trusted-law-firm-encourages-duolingo-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-duol.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A common stock of Duolingo, Inc. (NASDAQ: DUOL) between May 2, 2025 to February 26, 2026, inclusive (the “Class Period”), of the important December 7, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Baidu, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIDU 2026-10-24 · GlobeNewswire · Finance, Legal, Internet & apps https://www.globenewswire.com/news-release/2026/10/24/3387651/673/en/rosen-top-ranked-investor-counsel-encourages-baidu-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-bidu.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baidu, Inc. (NASDAQ: BIDU) between November 18, 2025 and August 17, 2026, inclusive (the “Class Period”), of the important November 13, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Gildan Activewear Inc. Securities Fraud Class Action Result of Alleged Channel Stuffing and 18.7% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/gildan-activewear-inc-securities-fraud-class-action-result-of-alleged-channel-stuffing-and-18-7-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302918524.html NEW ORLEANS, Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 14, 2026 to file lead plaintiff applications in a securities class... ———————————————————————————————————————————————————————————— Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline 2026-10-24 · PR Newswire · Legal https://www.prnewswire.com/news-releases/beta-bionics-inc-notice-of-november-3-2026-application-deadline-for-class-action-lawsuit---contact-lewis-kahn-esq-at-kahn-swick--foti-llc-before-application-deadline-302918521.html NEW YORK and NEW ORLEANS , Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NasdaqGM: BBNX) of a class action securities... ———————————————————————————————————————————————————————————— The Chemours Company Securities Fraud Class Action Result of Overstatement of Refrigerant Aftermarket Demand and 18% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/the-chemours-company-securities-fraud-class-action-result-of-overstatement-of-refrigerant-aftermarket-demand-and-18-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302918520.html NEW YORK and NEW ORLEANS , Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a... ———————————————————————————————————————————————————————————— Millrose Properties, Inc. Securities Fraud Class Action Result of Undisclosed Rental Home Business and 8.5% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/millrose-properties-inc-securities-fraud-class-action-result-of-undisclosed-rental-home-business-and-8-5-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302918519.html NEW YORK and NEW ORLEANS, Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 8, 2026 to file lead plaintiff applications in a... ———————————————————————————————————————————————————————————— Duolingo, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline 2026-10-24 · PR Newswire · Legal https://www.prnewswire.com/news-releases/duolingo-inc-notice-of-december-7-2026-application-deadline-for-class-action-lawsuit---contact-lewis-kahn-esq-at-kahn-swick--foti-llc-before-application-deadline-302918523.html NEW YORK and NEW ORLEANS , Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Duolingo, Inc. (NasdaqGS: DUOL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit... ———————————————————————————————————————————————————————————— York Space Systems, Inc. Notice of October 30, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline 2026-10-24 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/york-space-systems-inc-notice-of-october-30-2026-application-deadline-for-class-action-lawsuit---contact-lewis-kahn-esq-at-kahn-swick--foti-llc-before-application-deadline-302918522.html NEW YORK and NEW ORLEANS, Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in York Space Systems, Inc. ("York Space Systems" or the "Company") (NYSE: YSS) of a class action... ———————————————————————————————————————————————————————————— The Ensign Group, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline 2026-10-24 · PR Newswire · Legal https://www.prnewswire.com/news-releases/the-ensign-group-inc-notice-of-december-7-2026-application-deadline-for-class-action-lawsuit---contact-lewis-kahn-esq-at-kahn-swick--foti-llc-before-application-deadline-302918518.html NEW YORK and NEW ORLEANS , Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in The Ensign Group, Inc. (NasdaqGS: ENSG) of a class action securities lawsuit. CLASS DEFINITION: The... ———————————————————————————————————————————————————————————— Honeywell Aerospace, Inc. Notice of November 23, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline 2026-10-24 · PR Newswire · Industrial, Aerospace & defense, Legal https://www.prnewswire.com/news-releases/honeywell-aerospace-inc-notice-of-november-23-2026-application-deadline-for-class-action-lawsuit---contact-lewis-kahn-esq-at-kahn-swick--foti-llc-before-application-deadline-302918516.html NEW YORK and NEW ORLEANS, Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Honeywell Aerospace, Inc. ("Honeywell Aerospace" or the "Company") (NasdaqGS: HONA) of a class action... ———————————————————————————————————————————————————————————— Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC 2026-10-24 · PR Newswire · Finance, Healthcare, Legal https://www.prnewswire.com/news-releases/hims--hers-health-inc-securities-fraud-class-action-result-of-deceptive-privacy-and-billing-practices-and-over-14-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302918514.html NEW YORK and NEW ORLEANS, Oct. 23, 2026 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a... ———————————————————————————————————————————————————————————— ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Endava plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – DAVA 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387646/673/en/rosen-a-ranked-and-leading-law-firm-encourages-endava-plc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-dava.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Endava plc (NYSE: DAVA) between September 4, 2025 and September 21, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2026. ———————————————————————————————————————————————————————————— ROSEN, HIGHLY REGARDED INVESTOR RIGHTS COUNSEL, Encourages Dun & Bradstreet Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DNB 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387644/673/en/rosen-highly-regarded-investor-rights-counsel-encourages-dun-bradstreet-holdings-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-dnb.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that: (a) sold shares of Dun & Bradstreet Holdings, Inc. (NYSE: DNB) (“D&B”) common stock in the open market from May 13, 2025 through August 26, 2025; (b) exchanged shares of D&B common stock into the August 26, 2025 merger of D&B with affiliates of Clearlake Capital Group, L.P. for $9.15 per share in cash (the “Merger”); and/or (c) held shares of D&B common stock as of the May 9, 2025 Record Date for the special meeting of stockholders and whose shares were voted on, or entitled to vote on, the Merger, of the important November 10, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— ROSEN, REGARDED INVESTOR COUNSEL, Encourages AST SpaceMobile, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ASTS 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387641/673/en/rosen-regarded-investor-counsel-encourages-ast-spacemobile-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-asts.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AST SpaceMobile, Inc. (NASDAQ: ASTS) between March 4, 2025 and July 15, 2026, inclusive (the “Class Period”), of the important November 13, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fluence Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FLNC 2026-10-24 · GlobeNewswire · Finance, Energy, Legal https://www.globenewswire.com/news-release/2026/10/24/3387640/673/en/rosen-trusted-investor-counsel-encourages-fluence-energy-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-flnc.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fluence Energy, Inc. (NASDAQ: FLNC) between November 24, 2025 and September 16, 2026, inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— CELH DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Celsius Holdings, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - CELH 2026-10-24 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/24/3387638/673/en/celh-deadline-notice-rosen-a-global-and-leading-law-firm-encourages-celsius-holdings-inc-investors-to-secure-counsel-before-important-november-3-deadline-in-securities-class-action.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Celsius Holdings, Inc. (NASDAQ: CELH) between February 21, 2025 and June 3, 2026, both dates inclusive (the “Class Period”), of the important November 3, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Terrik Saint Claire Announces January Publication of The International Practitioner’s Sports Law Handbook 2026-10-24 · EIN Presswire · Sports, Legal, Entertainment https://www.einpresswire.com/article/951907115/terrik-saint-claire-announces-january-publication-of-the-international-practitioner-s-sports-law-handbook Terrik Saint Claire, international counsel working in entertainment and sports law. Terrik Saint Claire, international counsel working in entertainment and sports law. Terrik Saint Claire, international counsel working in entertainment and sports law. Former professional basketball player and international legal counsel examines the legal issues shaping sports, from representation to international competition Sports ———————————————————————————————————————————————————————————— DKS IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages DICK’S Sporting Goods, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DKS 2026-10-23 · GlobeNewswire · Finance, Sports, Legal https://www.globenewswire.com/news-release/2026/10/23/3387636/673/en/dks-important-deadline-rosen-recognized-investor-counsel-encourages-dick-s-sporting-goods-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-dks.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DICK’S Sporting Goods, Inc. (NYSE: DKS) between September 8, 2025 and August 24, 2026, both dates inclusive (the “Class Period”), of the important November 3, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Reid Collins & Tsai LLP Notifies Holders of Navios Maritime Holdings, Inc.’s Preferred ADS of Deficiencies in Navios’s Recent Tender Offer Documentation 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387635/0/en/reid-collins-tsai-llp-notifies-holders-of-navios-maritime-holdings-inc-s-preferred-ads-of-deficiencies-in-navios-s-recent-tender-offer-documentation.html NEW YORK, Oct. 23, 2026 -- Reid Collins & Tsai LLP (www.reidcollins.com, “Reid Collins”), a nationally recognized law firm handling high-stakes business litigation, informs beneficial holders (the “Preferred ADS Holders”) of American Depositary Shares (“ADS”) of the 8.75% Series G Cumulative Redeemable Perpetual Preferred Stock and the 8.625% Series H Cumulative Redeemable Perpetual Preferred Stock (the “Preferred Stock”) issued by Navios Maritime Holdings, Inc. (“Navios”) of deficiencies perceived in the offering document issued by Navios on October 9, 2026, regarding its $12.00 Offer to Purchase. ———————————————————————————————————————————————————————————— Robbins LLP Reminds PZZA Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Papa John's International, Inc. 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/robbins-llp-reminds-pzza-investors-of-the-pending-class-action-lawsuit-harmed-investors-should-contact-the-firm-for-information-about-leading-the-class-action-against-papa-johns-international-inc-302918465.html SAN DIEGO, Oct. 23, 2026 -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Papa John's International, Inc. (NASDAQ: PZZA) common stock between August 7, 2025 and... ———————————————————————————————————————————————————————————— ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages FuelCell Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FCEL 2026-10-23 · GlobeNewswire · Finance, Energy, Legal https://www.globenewswire.com/news-release/2026/10/23/3387627/673/en/rosen-top-ranked-global-counsel-encourages-fuelcell-energy-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-fcel.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities FuelCell Energy, Inc. (NASDAQ: FCEL) between June 24, 2026 and September 1, 2026, inclusive (the “Class Period”), of the important November 10, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— XTIA DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages XTI Aerospace, Inc. Investors to Secure Counsel Before Important October 27 Deadline in Securities Class Action - XTIA 2026-10-23 · GlobeNewswire · Finance, Aerospace & defense, Legal https://www.globenewswire.com/news-release/2026/10/23/3387626/673/en/xtia-deadline-notice-rosen-skilled-investor-counsel-encourages-xti-aerospace-inc-investors-to-secure-counsel-before-important-october-27-deadline-in-securities-class-action-xtia.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of XTI Aerospace, Inc. (NASDAQ: XTIA) between April 15, 2026 and August 17, 2026, both dates inclusive (the “Class Period”), of the important October 27, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Rodin Law Firm Nears Three Decades of Trial-Ready Civil Litigation in Alberta 2026-10-23 · PR Now · Legal https://pressreleasenews.org/pressroom/rodin-law-firm-nears-three-decades-of-trial-ready-civil-litigation-in-alberta A Calgary Firm Built for Complex, Contested Claims Reaffirms Its Focus as It Approaches Its 30th Year Calgary, AB, September 24, 2026 -- Rodin Law Firm, a Calgary-based civil litigation practice founded in 1997 by Greg Rodin, K.C., is approaching its 30th year of continuous opera… ———————————————————————————————————————————————————————————— Quest Diagnostics Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Unauthorized Access to Patient Records 2026-10-23 · PR Newswire · Healthcare, Cybersecurity, Legal, Medical devices https://www.prnewswire.com/news-releases/quest-diagnostics-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-unauthorized-access-to-patient-records-302918491.html National class action law firm offers free, confidential case evaluations to Quest Diagnostics patients and others whose information may have been exposed. SECAUCUS, N.J., Oct. 23, 2026 -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy... ———————————————————————————————————————————————————————————— Broussard Knoll Named People’s Choice of SWLA Winner for Third Consecutive Year 2026-10-23 · EIN Presswire · Legal https://www.einpresswire.com/article/951697710/broussard-knoll-named-people-s-choice-of-swla-winner-for-third-consecutive-year Broussard Knoll celebrates its third consecutive year of People’s Choice of SWLA honors, including Top Law Firm, Workers’ Compensation, Personal Injury and Best Attorney for Aaron Broussard. Southwest Louisiana law firm earns 4 community-voted honors, including Top Law Firm, Workers’ Compensation, Personal Injury & Best Attorney for Aaron Broussard LAKE CHARLES, LA, UNITED STATES, October 23, 2026 / EINPresswire.com ———————————————————————————————————————————————————————————— Modern Wealth Law Founder John Wong Recognized for Over 10 Years as a State Bar of California Certified Specialist 2026-10-23 · PR Newswire · Legal https://www.prnewswire.com/news-releases/modern-wealth-law-founder-john-wong-recognized-for-over-10-years-as-a-state-bar-of-california-certified-specialist-302918485.html Irvine estate planning attorney celebrates more than a decade of specialized certification in Estate Planning, Trust and Probate Law. IRVINE, Calif., Oct. 23, 2026 -- Modern Wealth Law, APLC, is proud to announce that its Founder and Managing Partner, John L. Wong, Esq., has... ———————————————————————————————————————————————————————————— Greenberg Traurig Represents PCS Wireless in Strategic Investment, Business Alliance with ReNet Japan Group 2026-10-23 · PR Newswire · Legal https://www.prnewswire.com/news-releases/greenberg-traurig-represents-pcs-wireless-in-strategic-investment-business-alliance-with-renet-japan-group-302918362.html TOKYO, Oct. 23, 2026 -- Global law firm Greenberg Traurig, LLP represented PCS Wireless, a leader in wireless device reuse and lifecycle management, in connection with its strategic investment in and business alliance with ReNet Japan Group Co., Ltd. (TSE: 3556), a publicly... ———————————————————————————————————————————————————————————— ZenaTech Unveils its Proprietary AI Software Suite Designed to Accelerate Land Survey Delivery for Drone as a Service Commercial, Municipal and Infrastructure Clients 2026-10-23 · ACN Newswire · Finance, AI, SaaS, Education, Industrial, Aerospace & defense, Logistics, Legal, Government & policy, Software & IT, Internet & apps, Construction & engineering, Agriculture https://www.acnnewswire.com/press-release/english/111043/ Vancouver, BC, Oct 24, 2026 - ZenaTech, Inc. (Nasdaq: ZENA)(FSE: 49Q)(BMV: ZENA)("ZenaTech" or the "Company"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today unveiled its proprietary artificial intelligence software suite and planned integration across its DaaS land survey operations. By pairing ZenaDrone high-density LiDAR (Light Detection and Ranging) data acquisition with automated feature extraction and point cloud classification, ZenaTech plans to accelerate survey-grade data delivery time from days to as little as minutes across commercial land surveying, municipal and infrastructure projects for DaaS clients across North America and around the world. The combined platform is currently in the development and testing stage. ZenaTech, Inc. is a B2i Digital Featured Company. See the company’s in-depth profile at: https://b2idigital.com/zenatech-1   “Land survey delivery has traditionally been limited by manual post-processing, which caps how many projects a survey team can complete,” said Shaun Passley, Ph.D., CEO of ZenaTech. “By integrating our AI software directly into ZenaDrone DaaS operations, we aimto automate the heavily manual work of point cloud classification and CAD linework generation, so the same crews and drones can deliver turn-key, actionable intelligence to clients faster and with consistent quality. As we apply our AI suite across our AI tools growing network of DaaS subsidiaries, we believe it can improve operating efficiency and support the scalable, recurring revenue model at the center of our DaaS strategy.” The combined platform is designed to bridge hardware data collection with AI-driven point cloud processing. A ZenaDrone land survey drone equipped with high-density LiDAR captures a site as a point cloud, a dataset that can contain billions of individual 3D measurement points. ZenaAI is then intended to run automated geospatial workflows on that data, classifying each point by what it represents, converting the classified data into terrain models and vector drawings, removing noise, tagging infrastructure assets and exporting the results in formats that survey and engineering teams can use directly. Its key planned capabilities include: Automated Point Cloud Classification: Designed to use deep learning neural networks to rapidly parse billions of 3D LiDAR points, separating ground returns from dense canopy, buildings, utility lines and surface vegetation to generate true Digital Terrain Models (DTM) Automated Feature Extraction and Linework: Computer vision algorithms are intended to detect and vectorize critical planimetric features, including curb lines, pavement edges, retaining walls and structures, and export them directly into CAD and BIM (Building Information Modeling) formats Rapid DaaS Turnaround: By replacing manual point-picking and heuristic scripting, the AI software suite is being designed to reduce post-processing workflows by as much as 80% and shorten survey turnaround time, allowing DaaS survey teams to deliver fully classified datasets within hours of flight completion Smart Noise Filtering and Asset Tagging: Automated artifact suppression is intended to clean airborne noise, multipath errors and scan overlap, while semantic tagging logs discrete infrastructure assets, such as manholes, hydrants and utility poles, with millimeter-level precision Point cloud classification and linework have traditionally required skilled technicians to work through by hand, which can take days and limits how many projects a survey team can complete. ZenaTech believes that automating these steps could raise surveying productivity, allowing the same drones and crews to deliver more projects faster and potentially improving margins over time. As proprietary software, the AI suite is also intended to add a scalable SaaS layer to the Company’s acquisition-led DaaS strategy, applying a consistent processing workflow across the surveying businesses it acquires and supporting its recurring revenue model for commercial, municipal and infrastructure clients that rely on timely data for planning, design and construction.   The AI-powered LiDAR processing is currently in development with testing across DaaS land surveying, infrastructure monitoring and utility inspection projects expected next year. The Company will provide updates on launch and rollout as milestones are achieved. ZenaTech’s Drone as a Service (DaaS) division provides on-demand turnkey drone piloting, data capture, and data processing services to commercial, government, and infrastructure customers, allowing them to access aerial data and automation without owning or operating their own drone fleets. The division is being built through an acquisition-led strategy that combines local low-tech service providers into a global network, creating a scalable platform for delivering recurring-revenue aerial and data services such as surveying, inspections, power washing, and construction progress monitoring. About ZenaTech ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company which specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives. Visit zenatech.com. About ZenaDrone ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, the IQ Aqua, for underwater applications, and the IQ Octo for precision agriculture. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system. Contacts Company, Investors and Media:  Linda Montgomery, ZenaTech, 312-241-1415 Investors:  Michael Mason, CORE IR, investors@zenatech.com Safe Harbor This press release and related comments by management of ZenaTech, Inc. include "forward-looking statements" within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management's expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities, including statements about the development, features, availability, pricing, commercialization and market adoption of ZenaAI. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; ZenaTech’s ability to deliver products to the market as currently contemplated, including software platforms such as ZenaAI; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; risks related to the development, testing, accuracy and performance of artificial intelligence and machine learning models; regulatory risks, including regulations governing drone operations; product development, validation and data quality and accuracy risks; customer adoption and recurring revenue opportunities; the competitive conditions of the industry; the ability to complete any contemplated acquisitions; market uncertainty; and applicable laws, regulations, and any amendments affecting the business of ZenaTech. Readers should not place undue reliance on forward-looking statements, which speak only as of the date of this release, and ZenaTech undertakes no obligation to update them except as required by law. Additional Contact: David Shapiro, B2i Digital, Inc., +1 212-579-4844, david@b2idigital.com B2i Digital Social Media: LinkedIn X Facebook Instagram YouTube TikTok Stocktwits Reddit Pinterest Threads To learn more about the B2i Digital Media Network, visit https://b2idigital.com/media-network. ———————————————————————————————————————————————————————————— Henderson, NV Asset Division In Divorce: Family Law Attorney Service Announced 2026-10-23 · MarketersMEDIA · Legal https://news.marketersmedia.com/henderson-nv-asset-division-in-divorce-family-law-attorney-service-announced/89207200 Henderson residents facing divorce involving substantial assets can now access asset-division representation from Leavitt Family Law Group (702-605-0065) as part of its wider family law services. -- Per the announcement, Leavitt Family Law Group is offering asset-division representation for Henderson residents facing high-net-worth divorce, with the firm handling matters involving closely held businesses, investment ———————————————————————————————————————————————————————————— Yiren Digital Ltd. Investor News: If You Have Suffered Losses in Yiren Digital Ltd., You Are Encouraged to Contact The Rosen Law Firm About Your Rights 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387587/673/en/yiren-digital-ltd-investor-news-if-you-have-suffered-losses-in-yiren-digital-ltd-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Yiren Digital Ltd. (NYSE: YRD) resulting from allegations that Yiren may have issued materially misleading business information to the investing public. ———————————————————————————————————————————————————————————— What Should Better Home & Finance Holding Company Investors Know After 28.5% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/what-should-better-home--finance-holding-company-investors-know-after-28-5-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302917689.html Lawsuit alleges Better Home & Finance Holding Company made misleading statements to investors from March 13, 2026 to May 7, 2026; lead plaintiff motions are due November 20, 2026 LOS ANGELES, Oct. 23, 2026 -- The Law Offices of Frank R. Cruz today announced a class action... ———————————————————————————————————————————————————————————— What Should Baidu, Inc. Investors Know After 12.73% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Legal, Internet & apps https://www.prnewswire.com/news-releases/what-should-baidu-inc-investors-know-after-12-73-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302917665.html Lawsuit alleges Baidu, Inc. made misleading statements to investors from November 18, 2025 to August 17, 2026; lead plaintiff motions are due November 13, 2026 LOS ANGELES, Oct. 23, 2026 -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Baidu,... ———————————————————————————————————————————————————————————— Kaplan Fox Encourages The Ensign Group, Inc. (NASDAQ: ENSG) Investors with Losses to Contact the Firm Before December 7, 2026 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387581/1020/en/kaplan-fox-encourages-the-ensign-group-inc-nasdaq-ensg-investors-with-losses-to-contact-the-firm-before-december-7-2026.html Kaplan Fox announces a securities class action against The Ensign Group (NASDAQ: ENSG) for investors from Feb. 10, 2022 to June 18, 2026. ———————————————————————————————————————————————————————————— What Should Bank Of America Corporation Investors Know After 4.76% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Banking, Legal https://www.prnewswire.com/news-releases/what-should-bank-of-america-corporation-investors-know-after-4-76-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302917646.html Lawsuit alleges Bank Of America Corporation made misleading statements to investors from August 1, 2025 to October 13, 2026; lead plaintiff motions are due December 15, 2026 LOS ANGELES, Oct. 23, 2026 -- The Law Offices of Frank R. Cruz today announced a class action lawsuit... ———————————————————————————————————————————————————————————— Kaplan Fox Notifies Millrose Properties, Inc. (NYSE: MRP) Investors of a Securities Class Action Deadline on December 8, 2026 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387579/1020/en/kaplan-fox-notifies-millrose-properties-inc-nyse-mrp-investors-of-a-securities-class-action-deadline-on-december-8-2026.html Kaplan Fox announces a securities class action against Millrose Properties (NYSE: MRP) for investors from Feb. 7, 2025 to Oct. 2, 2026. ———————————————————————————————————————————————————————————— Kaplan Fox Alerts Investors of Duolingo, Inc. (NASDAQ: DUOL) to a Pending Securities Class Action – Deadline is December 7, 2026 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387578/1020/en/kaplan-fox-alerts-investors-of-duolingo-inc-nasdaq-duol-to-a-pending-securities-class-action-deadline-is-december-7-2026.html Kaplan Fox announces a securities class action against Duolingo (NASDAQ: DUOL) for investors from May 2, 2025 to Feb. 26, 2026. ———————————————————————————————————————————————————————————— Elucid Statement on Heartflow Lawsuit: Reaffirms Mission, Confidence in Its Technology, and Commitment to Patients and Physicians 2026-10-23 · Business Wire · Real estate, Legal https://finance.yahoo.com/healthcare/articles/elucid-statement-heartflow-lawsuit-reaffirms-181500815.html BOSTON, October 23, 2026--Elucid Bioimaging Inc. ("Elucid") today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products. Elucid is aware of ———————————————————————————————————————————————————————————— What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Biotech & pharma, Legal https://www.prnewswire.com/news-releases/whats-next-for-unicycive-therapeutics-inc-shareholders-after-39-1-stock-drop-glancy-prongay-wolke--rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline-302917636.html Complaint alleges Unicycive Therapeutics, Inc. misled investors between December 29, 2025 and June 29, 2026; investors may seek lead plaintiff role by November 2, 2026 LOS ANGELES, Oct. 23, 2026 -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class... ———————————————————————————————————————————————————————————— Kaplan Fox Alerts Investors of Coastal Financial Corporation (NASDAQ: CCB) to a Pending Securities Class Action – Deadline is December 1, 2026 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387572/1020/en/kaplan-fox-alerts-investors-of-coastal-financial-corporation-nasdaq-ccb-to-a-pending-securities-class-action-deadline-is-december-1-2026.html Kaplan Fox announces a securities class action against Coastal Financial (NASDAQ: CCB) for investors from Oct. 28, 2024 to July 29, 2026. ———————————————————————————————————————————————————————————— What Does Gildan Activewear Inc.'s 18.8% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/what-does-gildan-activewear-incs-18-8-stock-drop-mean-for-investors-the-law-offices-of-howard-g-smith-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302917628.html Suit alleges Gildan Activewear Inc. failed to disclose key facts to investors from February 19, 2025 through June 15, 2026; lead plaintiff deadline is December 14, 2026 BENSALEM TOWNSHIP, Pa., Oct. 23, 2026 -- The Law Offices of Howard G. Smith today reported that a... ———————————————————————————————————————————————————————————— Kaplan Fox Alerts Investors of Alphabet Inc. (NASDAQ: GOOGL, GOOG) to a Pending Securities Class Action – Deadline is December 1, 2026 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387567/1020/en/kaplan-fox-alerts-investors-of-alphabet-inc-nasdaq-googl-goog-to-a-pending-securities-class-action-deadline-is-december-1-2026.html Kaplan Fox announces a securities class action against Alphabet (NASDAQ: GOOGL) for investors from May 19, 2026 to July 16, 2026. ———————————————————————————————————————————————————————————— What Does Netcapital Inc.'s 28.62% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/what-does-netcapital-incs-28-62-stock-drop-mean-for-investors-the-law-offices-of-howard-g-smith-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302917638.html Suit alleges Netcapital Inc. failed to disclose key facts to investors from December 15, 2021 through September 3, 2026; lead plaintiff deadline is December 7, 2026 BENSALEM TOWNSHIP, Pa., Oct. 23, 2026 -- The Law Offices of Howard G. Smith today reported that a securities... ———————————————————————————————————————————————————————————— What Does Alphabet Inc.'s 7.13% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/what-does-alphabet-incs-7-13-stock-drop-mean-for-investors-the-law-offices-of-howard-g-smith-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302917641.html Suit alleges Alphabet Inc. failed to disclose key facts to investors from May 19, 2026 through July 16, 2026; lead plaintiff deadline is December 1, 2026 BENSALEM TOWNSHIP, Pa., Oct. 23, 2026 -- The Law Offices of Howard G. Smith today reported that a securities class action... ———————————————————————————————————————————————————————————— What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/what-does-anavex-life-sciences-corps-6-35-stock-drop-mean-for-investors-the-law-offices-of-howard-g-smith-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302917616.html Suit alleges Anavex Life Sciences Corp. failed to disclose key facts to investors from November 26, 2025 through August 28, 2026; lead plaintiff deadline is November 30, 2026 BENSALEM TOWNSHIP, Pa., Oct. 23, 2026 -- The Law Offices of Howard G. Smith today reported that a... ———————————————————————————————————————————————————————————— The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme 2026-10-23 · Business Wire · Biotech & pharma, Legal https://finance.yahoo.com/healthcare/articles/lanier-law-firm-supports-attorney-172700408.html Litigation sought reimbursements for violations of state law in prescribing practices, charges to Medicaid program HOUSTON, October 23, 2026--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal ———————————————————————————————————————————————————————————— ASTS Deadline in 21 Days: AST SpaceMobile, Inc. (ASTS) Securities Fraud Class Action Lawsuit Filed; November 13, 2026, Lead Plaintiff Deadline - Kessler Topaz Meltzer & Check, LLP 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387558/0/en/asts-deadline-in-21-days-ast-spacemobile-inc-asts-securities-fraud-class-action-lawsuit-filed-november-13-2026-lead-plaintiff-deadline-kessler-topaz-meltzer-check-llp.html Did you buy ASTS securities between March 4, 2025 and July 15, 2026? ———————————————————————————————————————————————————————————— Hazen Law Group Announces Publication Detailing Marielle Hazen’s Appointment as National Academy of Elder Law Attorneys President 2026-10-23 · EIN Presswire · Legal https://www.einpresswire.com/article/951819449/hazen-law-group-announces-publication-detailing-marielle-hazen-s-appointment-as-national-academy-of-elder-law-attorneys-president Harrisburg, Pennsylvania – The National Academy of Elder Law Attorneys has formally introduced Marielle F. Hazen , founder of Hazen Law Group , as the organization’s 39th president in the latest issue of NAELA News. The featured article , published in the July through September 2026 edition of the organization’s quarterly journal, chronicles Hazen’s decades of leadership at both state and national levels, marking a s ———————————————————————————————————————————————————————————— bp and the State of Louisiana agree to resolve long-standing matters and open a new chapter 2026-10-23 · PR Newswire · Legal https://www.prnewswire.com/news-releases/bp-and-the-state-of-louisiana-agree-to-resolve-long-standing-matters-and-open-a-new-chapter-302918333.html Agreement gives Louisiana its remaining Deepwater Horizon economic damages payments in a single early payment and resolves the remaining coastal zone lawsuits involving bp HOUSTON, Oct. 23, 2026 -- bp and the State of Louisiana ('Louisiana') today announced an agreement to... ———————————————————————————————————————————————————————————— Coastal Financial Corporation (CCB) Faces Securities Class Action Amid Scrutiny Over BaaS Credit Risk Management Effectiveness, Shares Tank 43% 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/coastal-financial-corporation-ccb-faces-securities-class-action-amid-scrutiny-over-baas-credit-risk-management-effectiveness-shares-tank-43-302918218.html SAN FRANCISCO, Oct. 23, 2026 -- Coastal Financial Corporation (NASDAQ: CCB) faces a securities class action lawsuit that seeks to represent investors who purchased or otherwise acquired shares of Coastal common stock between October 28, 2024 and July 29, 2026. The lawsuit... ———————————————————————————————————————————————————————————— HIMS 10-DAY DEADLINE ALERT: Hims & Hers Health Facing Securities Class Action Lawsuit, Investors with Losses Encouraged to Contact Hagens Berman 2026-10-23 · PR Newswire · Finance, Healthcare, Legal https://www.prnewswire.com/news-releases/hims-10-day-deadline-alert-hims--hers-health-facing-securities-class-action-lawsuit-investors-with-losses-encouraged-to-contact-hagens-berman-302918171.html SAN FRANCISCO, Oct. 23, 2026 -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business... ———————————————————————————————————————————————————————————— DEADLINE ALERT for The Chemours Company (CC), Compass, Inc. (COMP), and Millrose Properties, Inc. (MRP): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387534/0/en/deadline-alert-for-the-chemours-company-cc-compass-inc-comp-and-millrose-properties-inc-mrp-the-law-offices-of-frank-r-cruz-reminds-investors-of-lead-plaintiff-deadlines-in-securit.html Investors in The Chemours Company, Compass, Inc., and Millrose Properties, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in The Chemours Company, Compass, Inc., and Millrose Properties, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions ———————————————————————————————————————————————————————————— APP SHAREHOLDER NOTICE: AppLovin Corporation Investors with Substantial Losses Have Opportunity to Lead the APP Securities Class Action 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/app-shareholder-notice-applovin-corporation-investors-with-substantial-losses-have-opportunity-to-lead-the-app-securities-class-action-302918172.html SAN FRANCISCO, Oct. 23, 2026 -- AppLovin Corporation (NASDAQ: APP) faces a securities class action seeking to represent investors who purchased or otherwise acquired AppLovin securities between February 12, 2026 and August 5, 2026. The suit follows the publication of a... ———————————————————————————————————————————————————————————— DEADLINE ALERT for Gildan Activewear Inc. (GIL), D-Wave Quantum, Inc. (QBTS), and Bank Of America Corporation (BAC): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions 2026-10-23 · GlobeNewswire · Banking, Legal https://www.globenewswire.com/news-release/2026/10/23/3387533/0/en/deadline-alert-for-gildan-activewear-inc-gil-d-wave-quantum-inc-qbts-and-bank-of-america-corporation-bac-the-law-offices-of-frank-r-cruz-reminds-investors-of-lead-plaintiff-deadlin.html Investors in Gildan Activewear Inc., D-Wave Quantum, Inc., and Bank Of America Corporation have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in Gildan Activewear Inc., D-Wave Quantum, Inc., and Bank Of America Corporation have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions ———————————————————————————————————————————————————————————— BETR SHAREHOLDER NOTICE: Better Home & Finance Holding Company Investors Alerted to Nov. 20, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/betr-shareholder-notice-better-home--finance-holding-company-investors-alerted-to-nov-20-2026-lead-plaintiff-deadline-in-securities-fraud-class-action-302918173.html SAN FRANCISCO, Oct. 23, 2026 -- Better Home & Finance (NASDAQ: BETR) faces a securities class action after it reported that its Q1 2026 net loss increased 75% sequentially (and 39% year over year) and drastically walked back on assurances of $1 billion monthly loan volume by... ———————————————————————————————————————————————————————————— Hagens Berman, National Trial Attorneys, Encourages Bank of America (BAC) Investors With Substantial Losses To Contact Firm Prior To Dec. 15 Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Banking, Legal https://www.prnewswire.com/news-releases/hagens-berman-national-trial-attorneys-encourages-bank-of-america-bac-investors-with-substantial-losses-to-contact-firm-prior-to-dec-15-lead-plaintiff-deadline-302918170.html SAN FRANCISCO, Oct. 23, 2026 -- National securities litigation law firm Hagens Berman alerts investors in Bank of America Corporation (NYSE: BAC) to a securities class action lawsuit filed in federal court against Bank of America and certain senior executives alleging... ———————————————————————————————————————————————————————————— Hagens Berman, National Trial Attorneys, Encourages Gildan Activewear Inc. (GIL) Investors With Substantial Losses To Contact Firm Prior To Dec. 14 Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/hagens-berman-national-trial-attorneys-encourages-gildan-activewear-inc-gil-investors-with-substantial-losses-to-contact-firm-prior-to-dec-14-lead-plaintiff-deadline-302918167.html SAN FRANCISCO, Oct. 23, 2026 -- Hagens Berman, a prominent national trial law firm specializing in securities fraud and shareholder rights, alerts investors in Gildan Activewear Inc. (NYSE: GIL) to a class action lawsuit filed in federal court. The firm encourages Gildan... ———————————————————————————————————————————————————————————— Fluence Energy (NASDAQ: FLNC) Facing Securities Class Action Amid Inability to Ramp Houston Facility 2026-10-23 · PR Newswire · Finance, Energy, Legal https://www.prnewswire.com/news-releases/fluence-energy-nasdaq-flnc-facing-securities-class-action-amid-inability-to-ramp-houston-facility-302918162.html SAN FRANCISCO, Oct. 23, 2026 -- Fluence Energy (NASDAQ: FLNC) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired Fluence securities between November 24, 2025 and September 16, 2026. The suit follows a stream of unexpected... ———————————————————————————————————————————————————————————— Sexual Assault Lawyer Philadelphia: David P. Thiruselvam of the Victims’ Recovery Law Center Fights for Survivors' Civil Rights 2026-10-23 · Newswire.com · Legal https://www.newswire.com/news/sexual-assault-lawyer-philadelphia-david-p-thiruselvam-of-the-victims-22877421 Survivors of sexual assault in Philadelphia have civil legal options that exist completely independently of the criminal justice system, and the Victims' Recovery Law Center is here to pursue them. ———————————————————————————————————————————————————————————— Verisk Comments on Delaware Supreme Court Order Regarding AccuLynx 2026-10-23 · GlobeNewswire · Finance, Insurance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387525/0/en/verisk-comments-on-delaware-supreme-court-order-regarding-acculynx.html JERSEY CITY, N.J., Oct. 23, 2026 -- Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, today issued the following statement in response to the Delaware Supreme Court order regarding the AccuLynx transaction: ———————————————————————————————————————————————————————————— 1 WEEK YSS INVESTOR DEADLINE: York Space Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before October 30, 2026 Deadline 2026-10-23 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/1-week-yss-investor-deadline-york-space-systems-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-before-october-30-2026-deadline-302917618.html SAN DIEGO, Oct. 23, 2026 -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent: (i) all purchasers of York Space Systems, Inc. (NYSE: YSS) common stock in or traceable to York Space's January 2026 initial... ———————————————————————————————————————————————————————————— Labor & Employment Law Firm Zakay Law Group, APLC Files a Class Action Against Mendocino Farms, Alleging Failure to Provide Meal and Rest Breaks 2026-10-23 · PR Newswire · Legal, Agriculture https://www.prnewswire.com/news-releases/labor--employment-law-firm-zakay-law-group-aplc-files-a-class-action-against-mendocino-farms-alleging-failure-to-provide-meal-and-rest-breaks-302917586.html The lawsuit alleges Mendocino Farms violated the California Labor Code by failing to pay its employees for all time worked. ALAMEDA, Calif., Oct. 23, 2026 -- The Alameda labor law attorneys at Zakay Law Group, APLC, filed a class action complaint against Mendocino Farms, LLC... ———————————————————————————————————————————————————————————— International Debt Recovery: Settlement Reached in a High-Value European B2B Dispute 2026-10-23 · ACCESS Newswire · Legal https://finance.yahoo.com/small-business/articles/international-debt-recovery-settlement-reached-153000097.html WEESP, NL / October 23, 2026 / A cross-border commercial dispute involving a claim exceeding €800,000, fully contested by the opposing party, was resolved through a negotiated settlement and a structured repayment plan. The negotiations were handled by Basile International Legal Firm , founded by attorney Marco Basile and active in international B2B debt recovery and cross-border commercial disputes ———————————————————————————————————————————————————————————— BETR Investors Have Opportunity to Lead Better Home & Finance Holding Company Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387493/0/en/betr-investors-have-opportunity-to-lead-better-home-finance-holding-company-securities-fraud-lawsuit-with-sbs-law.html BETR Investors Have Opportunity to Lead Better Home & Finance Holding Company Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— HONA Investors Have Opportunity to Lead Honeywell Aerospace Inc. Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Industrial, Aerospace & defense, Legal https://www.globenewswire.com/news-release/2026/10/23/3387491/0/en/hona-investors-have-opportunity-to-lead-honeywell-aerospace-inc-securities-fraud-lawsuit-with-sbs-law.html HONA Investors Have Opportunity to Lead Honeywell Aerospace Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387489/0/en/ardx-investors-have-opportunity-to-lead-ardelyx-inc-securities-fraud-lawsuit-with-sbs-law.html ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387488/0/en/docs-investors-have-opportunity-to-lead-doximity-inc-securities-fraud-lawsuit-with-sbs-law.html DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— APP Investors Have Opportunity to Lead AppLovin Corporation Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387487/0/en/app-investors-have-opportunity-to-lead-applovin-corporation-securities-fraud-lawsuit-with-sbs-law.html APP Investors Have Opportunity to Lead AppLovin Corporation Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— ASTS Investors Have Opportunity to Lead AST SpaceMobile, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387486/0/en/asts-investors-have-opportunity-to-lead-ast-spacemobile-inc-securities-fraud-lawsuit-with-sbs-law.html ASTS Investors Have Opportunity to Lead AST SpaceMobile, Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— BIDU Investors Have Opportunity to Lead Baidu, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Legal, Internet & apps https://www.globenewswire.com/news-release/2026/10/23/3387485/0/en/bidu-investors-have-opportunity-to-lead-baidu-inc-securities-fraud-lawsuit-with-sbs-law.html BIDU Investors Have Opportunity to Lead Baidu, Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— Atlanta Tax Attorney Office Opened by J. David Tax Law for IRS and Georgia Department of Revenue Tax Debt Resolution 2026-10-23 · EIN Presswire · Finance, Legal https://www.einpresswire.com/article/951802234/atlanta-tax-attorney-office-opened-by-j-david-tax-law-for-irs-and-georgia-department-of-revenue-tax-debt-resolution J. David Tax Law's Atlanta Office J. David Tax Law Jonathan David Sooriash, CEO and Founder of J. David Tax Law Atlanta tax lawyers handle IRS OIC, installment agreements, tax lien and levy releases, penalty abatement and GDOR disputes from a new Cumberland-area office. The Department of Revenue can record a state tax lien and move to levies and garnishments. We opened in Atlanta so people across the metro area can r ———————————————————————————————————————————————————————————— Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Act Ahead of the Lead Plaintiff Deadline on November 3, 2026 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387484/1020/en/kaplan-fox-encourages-investors-of-beta-bionics-inc-nasdaq-bbnx-to-act-ahead-of-the-lead-plaintiff-deadline-on-november-3-2026.html Kaplan Fox announces a securities class action against Beta Bionics (NASDAQ: BBNX) for investors from July 30, 2025 to Feb. 24, 2026. ———————————————————————————————————————————————————————————— LINC Investors Have Opportunity to Lead Lincoln Educational Services Corporation Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387483/0/en/linc-investors-have-opportunity-to-lead-lincoln-educational-services-corporation-securities-fraud-lawsuit-with-sbs-law.html LINC Investors Have Opportunity to Lead Lincoln Educational Services Corporation Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— TruGolf Holdings (TRUG) Expands E6 Golf Library to More Than 15,000 Courses, Reports Increased Platform Usage 2026-10-23 · NewMediaWire · Finance, AI, SaaS, Gaming, Media, Education, Sports, Legal, Software & IT https://www.newmediawire.com/news/trugolf-holdings-trug-expands-e6-golf-library-to-more-than-15-000-courses-reports-increased-platform-usage-7090833 LOS ANGELES, CA - October 23, 2026 - TruGolf (NASDAQ: TRUG) announced that its E6 golf simulation platform now offers more than 15,000 real-world courses on demand, a 50% increase in less than a year. Powered by Cesium for Unreal technology from Bentley Systems Inc., the platform generates courses at runtime and streams geographic data as needed, reducing installation size, bandwidth requirements and storage costs. E6 supports 19 launch monitors, allowing golfers using hardware from multiple manufacturers to access the expanding course library, which is also available throughout the TruGolf Links franchise network. The company reported that on-demand course play increased nearly sixfold year over year, while the number of courses explored grew more than fourfold and shots played on on-demand courses rose more than sevenfold. Total rounds played on E6 Golf 2026 more than tripled, with on-demand courses accounting for over 40% of course rounds, compared with approximately 30% a year earlier. TruGolf said the expanding library supports its recurring software business by making additional courses available to existing subscribers and venues without requiring larger software installations. To view the full press release, visit: https://ibn.fm/IQnwH About TruGolf Since 1983, TruGolf has been passionate about driving the golf industry with innovative indoor golf solutions. TruGolf builds products that capture the spirit of golf. TruGolf’s mission is to help grow the game by attempting to make it more Available, Approachable, and Affordable through technology – because TruGolf believes Golf is for Everyone. TruGolf’s team has built award-winning video games (“Links”), innovative hardware solutions, and an all-new e-sports platform, E6 CONNECT, to connect golfers around the world. Since TruGolf’s beginning, TruGolf has continued to attempt to define and redefine what is possible with golf technology. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to TRUG are available in the company’s newsroom at https://ibn.fm/TRUG Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— Bronstein, Gewirtz & Grossman LLC Urges Celsius Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm 2026-10-23 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/23/3387475/9788/en/bronstein-gewirtz-grossman-llc-urges-celsius-holdings-inc-investors-to-act-class-action-filed-alleging-investor-harm.html New class action for Celsius (CELH) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/3/2026 ———————————————————————————————————————————————————————————— Kaplan Fox Urges AppLovin Corporation (NASDAQ: APP) Investors Seeking Recovery to Contact the Firm Before November 16, 2026 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387473/1020/en/kaplan-fox-urges-applovin-corporation-nasdaq-app-investors-seeking-recovery-to-contact-the-firm-before-november-16-2026.html Kaplan Fox announces a securities class action against AppLovin (NASDAQ: APP) for investors from Feb. 12, 2026 to Aug. 5, 2026. ———————————————————————————————————————————————————————————— Invictus Investment Enters Into Agreement With Helios Investment Partners for Minority Stake in Merec Industries 2026-10-23 · APO Group · Finance, SaaS, Retail, Food & drink, Industrial, Sustainability, Investing & markets, Legal, Agriculture https://www.africa-newsroom.com/press/invictus-investment-enters-into-agreement-with-helios-investment-partners-for-minority-stake-in-merec-industries?lang=en Helios to acquire a significant minority stake in Merec Industries, Mozambique’s largest flour milling company Partnership combines Invictus Investment’s sector knowledge and operational capabilities with Helios’ extensive experience across Africa to support Merec Industries’ growth in Mozambique and the wider region Transaction expected to close by the end of 2026, subject to customary closing conditions, including regulatory approvals Invictus Investment (ADX: INVICTUS) (https://invictusinvestment.ae), a leading holding company specialised in agro-food commodities across the Middle East and Africa, and Helios Investment Partners (“Helios”), a leading Africa-focused private investment firm, today announced that Helios Fund V (“Helios V”) has entered into an agreement to acquire up to a 49% interest in Stratton Africa Holdings Limited, the Mauritius-incorporated holding company of Merec Industries (“Merec”), from Invictus Investment. The transaction is expected to close by the end of 2026, subject to customary closing conditions, including regulatory approvals, after which Invictus Investment will remain the majority shareholder. Founded in 1998, Merec is Mozambique’s largest flour milling company, processing wheat and corn into an integrated product portfolio spanning flour, pasta, biscuits and animal feed. Its mills, production facilities and silos are strategically located in each of Mozambique’s three principal port regions: Beira, Maputo and Nacala – making it the only miller with manufacturing facilities in all three. Merec also owns a grain terminal at the port of Maputo. This footprint supports a nationwide distribution network serving wholesalers, retailers, bakeries, feed producers and distributors, underlining Merec’s important role in the production and supply of essential food products across Mozambique. Invictus Investment acquired Merec in January 2025 through the purchase of its holding company, Stratton Africa Holdings Limited, as part of its strategy to expand its agro-food business in high-potential African markets and strengthen its capabilities across the value chain. Since the acquisition, Merec’s operating performance has improved significantly, and this has prompted a more ambitious growth strategy to expand the business beyond its core operations into new food categories in Mozambique and across the wider Southern African Development Community (“SADC”) region. The new partnership will support these plans by combining Invictus Investment’s expertise across the agro-food value chain with Helios’ track record of investing in and supporting market-leading businesses across Africa. Together, the shareholders will also work on furthering Merec’s governance framework, leadership capabilities, ESG practices and broader development impact. Commenting on the announcement, Amir Daoud Abdellatif, CEO of Invictus Investment, said: “We welcome Helios, one of Africa’s leading private equity investors, as our partner in the expansion of Merec. With its strong focus on high-growth sectors across the continent, Helios’ regional expertise will be instrumental in accelerating Merec’s next phase of growth. Since Invictus Investment’s acquisition of Merec, its position as Mozambique’s largest flour milling company has been strengthened and consolidated, and now, our shared ambition with Helios is to build on the business’s contribution to food security and local employment in Mozambique and develop it into a regional food platform for Southern Africa. This partnership aligns perfectly with our strategic approach to acquisitions, which has always been to build strong businesses alongside high-calibre partners that support our long-term vision of building a fully integrated agro-food enterprise.” Tope Lawani, Co-Founder and Managing Partner of Helios Investment Partners, added: “Merec has built a distinctive position in Mozambique, with a nationwide footprint, strong brands and an important role in the country’s staple foods market. The consumer non-discretionary sector is a key strategic focus for Helios, and we bring a proven track record of investing in and scaling resilient businesses that serve essential consumer needs across Africa. We see significant opportunity to build on Merec’s strengths and are pleased to partner with Invictus Investment and the management team to support the company’s next phase of growth.” Akin Gump Strauss Hauer & Feld is acting as legal counsel to Helios, with GDA Advogados as Mozambican counsel. Freshfields is acting as legal counsel to Invictus Investment. *Please refer to heliosinvestment.com/news and invictusinvestment.ae/investor-relations/ for more information. Distributed by APO Group on behalf of Invictus Investment Company PLC. For further information, please contact: Helios Investment Partners About Invictus Investment: https://apo-opa.co/4BmtcHf About Helios Investment Partners: Since 2004, Helios has applied its investment capabilities, entrepreneurial business-building expertise and local and global connectivity to generate competitive returns and positive impact across Africa. The firm is a certified B Corp, reflecting its long-standing commitment to sustainability and responsible business practices. ———————————————————————————————————————————————————————————— In HelloNation, Estate Planning Attorney Aaron Miller Offers Tips for Elder Law Planning 2026-10-23 · PR Newswire · Legal https://www.prnewswire.com/news-releases/in-hellonation-estate-planning-attorney-aaron-miller-offers-tips-for-elder-law-planning-302882986.html The article outlines practical elder law steps involving long-term care planning, healthcare decisions, and financial preparation. DALLAS, Oct. 23, 2026 -- What practical legal steps can families take today to prepare for future healthcare and financial challenges?... ———————————————————————————————————————————————————————————— DR²SPINE Opens Subspecialty IME Referrals for Disputed Spine and Musculoskeletal Claims 2026-10-23 · PR Now · Insurance, Legal https://pressreleasenews.org/pressroom/dr-spine-opens-subspecialty-ime-referrals-for-disputed-spine-and-musculoskeletal-claims Double board-certified pain specialist Dr. Myrdalis Díaz-Ramírez now accepts case referrals from law firms, insurers, and employers that need a clinically defensible opinion on complex spine injuries. Tucson, AZ, September 7, 2026 - DR²SPINE, a regenerative medicine practice base… ———————————————————————————————————————————————————————————— Asset Search USA Publishes Free Guide on How to Find Hidden Assets Before and After Judgment 2026-10-23 · PR Newswire · Real estate, Legal https://www.prnewswire.com/news-releases/asset-search-usa-publishes-free-guide-on-how-to-find-hidden-assets-before-and-after-judgment-302917571.html Nationwide asset investigation firm publishes a practical guide covering concealed property, shell entities, cryptocurrency and transfer timing, written for attorneys evaluating cases and enforcing judgments. NASHVILLE, Tenn., Oct. 23, 2026 -- Asset Search USA™ by Carl Mason... ———————————————————————————————————————————————————————————— Chinatown Seniors, Community Leaders Sue to End Years of Planned Nighttime Construction to Complete Delayed Manhattan Megajail 2026-10-23 · PR Newswire · Legal, Construction & engineering https://www.prnewswire.com/news-releases/chinatown-seniors-community-leaders-sue-to-end-years-of-planned-nighttime-construction-to-complete-delayed-manhattan-megajail-302918112.html City's Six Years of 23-Hour Workdays Violate Environmental Review Laws NEW YORK, Oct. 23, 2026 -- Chinatown seniors and community leaders announced a lawsuit to stop the City's years of planned overnight construction of the long-delayed Manhattan "Megajail." The Article 78... ———————————————————————————————————————————————————————————— Veteran Sarasota Trial Attorney Patricia D. Crauwels Available for Mediation Through UWWM 2026-10-23 · iCrowdNewswire · Legal https://icrowdnewswire.com/2026/10/23/veteran-sarasota-trial-attorney-patricia-d-crauwels-available-for-mediation-through-uwwm/ SARASOTA, Fla. (October 23, 2026) – Patricia D. Crauwels, a veteran civil trial attorney and Florida Supreme Court Certified Circuit Civil Mediator, is accepting mediation appointments through her recent affiliation with Upchurch Watson White & Max Mediation Group (UWWM). Based […] ———————————————————————————————————————————————————————————— Shareholders who lost money in shares of Triller Group Inc. (OTC BB: ILLR) should contact Wolf Haldenstein Immediately 2026-10-23 · PR Newswire · Legal https://www.prnewswire.com/news-releases/shareholders-who-lost-money-in-shares-of-triller-group-inc-otc-bb-illr-should-contact-wolf-haldenstein-immediately-302917602.html Lead Plaintiff Deadline December 14, 2026 NEW YORK, Oct. 23, 2026 -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the United States... ———————————————————————————————————————————————————————————— Dialogica Founder Partners with Silicon Valley GTM Expert Dylan Gittleman to Donate Equity Toward New Synagogue and Community Kitchen in Monticello, NY 2026-10-23 · PR Newswire · AI, Banking, Legal https://www.prnewswire.com/news-releases/dialogica-founder-partners-with-silicon-valley-gtm-expert-dylan-gittleman-to-donate-equity-toward-new-synagogue-and-community-kitchen-in-monticello-ny-302917428.html SANTA MONICA, Calif., Oct. 23, 2026 -- Dialogica ("Dia"), the voice-first AI secretary for the world's top law firms, today announced that Silicon Valley go-to-market business development Investment Banker, Dylan Gittleman is partnering with Dia's founder Austin Worrell, to... ———————————————————————————————————————————————————————————— Barentsz Advances Legal AI Development to Empower Law Firms Worldwide 2026-10-23 · MarketersMEDIA · AI, Legal, Software & IT https://news.marketersmedia.com/barentsz-advances-legal-ai-development-to-empower-law-firms-worldwide/89207122 -- Barentsz, a global business and strategic consulting firm, has announced its initiative to develop artificial intelligence solutions specifically designed for the legal industry. The initiative aims to empower law firms worldwide by integrating advanced AI technologies into legal workflows, enhancing operational efficiency, and supporting the digital transformation of legal services. As artificial intelligence con ———————————————————————————————————————————————————————————— Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA 2026-10-23 · PressReach · Finance, Healthcare, Food & drink, Biotech & pharma, Legal https://pressreach.com/phathom-pharmaceuticals-provides-update-on-litigation-filed-by-bdr-pharmaceuticals-against-fda FLORHAM PARK, N.J., Oct. 23, 2026 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United … Continue reading "Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA" ———————————————————————————————————————————————————————————— Erika A. MacLeod's Journey as an Experienced Divorce Lawyer in Guelph 2026-10-23 · PRUnderground · Legal https://prunderground.com/erika-a-macleod-s-journey-as-an-experienced-divorce-lawyer-in-guelph/cmvkggs2b000007jtyn2m56u1 The post Erika A. MacLeod's Journey as an Experienced Divorce Lawyer in Guelph first appeared on ———————————————————————————————————————————————————————————— SignalHire records higher Legal Services, Financial Services, and Accounting search activity in H1 2026 2026-10-23 · EIN Presswire · Legal, Jobs & workplace https://www.einpresswire.com/article/951712615/signalhire-records-higher-legal-services-financial-services-and-accounting-search-activity-in-h1-2026 Legal Services grew 95.05%, Financial Services 72.52%, and Accounting 10.77% in H1 2026. Legal and finance searches rose while overall activity fell. Employers should check the work behind each opening before changing their hiring plans.” — Ruslan Farakheiev SAN FRANCISCO, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- SignalHire ’s first-half category comparison shows increases of 95.05% for Legal Servi ———————————————————————————————————————————————————————————— Alkagesta Acquires Turkish Marine Fuel Distribution Company Energy Petrol 2026-10-23 · Pressat · Finance, SaaS, Energy, Aerospace & defense, Investing & markets, Legal, Oil & gas https://pressat.co.uk/releases/alkagesta-acquires-turkish-marine-fuel-distribution-company-energy-petrol-d71defacbca02e9e60457f42dd92d572/ Friday 23 October, 2026 Malta, 22 October 2026 Alkagesta, the international energy and commodity trading house headquartered in Malta, has agreed to acquire Energy Petrol, a Turkish marine fuel distribution company. The deal, covered by Bloomberg, marks the company’s first move into vessel ownership and expands its presence across the Mediterranean marine fuel supply market. The transaction has been approved by Turkey’s antitrust watchdog. Financial terms were not disclosed. The acquisition includes Energy Petrol’s fleet of eight marine fuel vessels, bringing total global oil products storage capacity across the Alkagesta platform to approximately 728,000 cubic metres. Energy Petrol will continue to operate independently following the transaction. The deal expands the company’s model from trading marine fuel to distributing it directly to end-users. Asad Huseynov, Managing Director of Investments and Asset Management at Alkagesta, noted the acquisition lays the ground for potential future investments or structured partnerships in other infrastructure-style assets. Alkagesta currently supplies approximately 40% of Turkey’s 2.5 million tonne per year marine fuel market and approximately 75% of Malta’s, with plans to expand marine fuel supply operations in Singapore — where the hub reached approximately 250,000 metric tonnes per month in its first full year. The acquisition builds on a record first half of 2026, during which Alkagesta secured access to the NATO Central Europe Pipeline System for Jet A1 deliveries and completed its first crude oil transactions. ———————————————————————————————————————————————————————————— Wisconsin Real Estate Teams Are Invisible to AI-Powered Buyers. Sinc Media Is Addressing That. 2026-10-23 · PR Now · AI, Real estate, Legal, Marketing & advertising https://pressreleasenews.org/pressroom/wisconsin-real-estate-teams-are-invisible-to-ai-powered-buyers-sinc-media-is-addressing-that Timothy Blank, attorney and founder of Sinc Media, LLC, explains why Wisconsin real estate team leaders who are still measuring marketing success by Google rankings alone are missing the buyers who've already moved on to AI tools for local recommendations. Sinc Media, LLC today a… ———————————————————————————————————————————————————————————— Raleigh Criminal Defense Attorney Christopher Detwiler Awarded 2026 Client's Choice by AVVO 2026-10-23 · MarketersMEDIA · Legal https://news.marketersmedia.com/raleigh-criminal-defense-attorney-christopher-detwiler-awarded-2026-clients-choice-by-avvo/89207105 -- The Avvo recognition marks Attorney Detwiler’s second straight year receiving the award, based on positive client reviews of his criminal defense work. Raleigh criminal defense attorney Christopher R. Detwiler has earned the 2026 Avvo Clients’ Choice Award, marking his second consecutive year receiving the client-based recognition. The annual award is based on reviews submitted by people who have worked directly w ———————————————————————————————————————————————————————————— Nasser Abujbarah of Phillips Law Group Named 2026 Medium-size Business Leader of the Year 2026-10-23 · EIN Presswire · Legal https://www.einpresswire.com/article/944696879/nasser-abujbarah-of-phillips-law-group-named-2026-medium-size-business-leader-of-the-year Phillips Law Group marks Nasser Abujbarah’s 2026 Champions of Change recognition. Az Business magazine, a publication of AZ Big Media, recognized Abujbarah at the completed May 21 Champions of Change Awards. PHOENIX, AZ, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Az Business magazine , a publication of AZ Big Media, named Nasser Abujbarah of Phillips Law Group – Injury Lawyers its 2026 Medium-size Busine ———————————————————————————————————————————————————————————— Holiday Parenting Time in New Jersey: Law Offices of Sylvia Costantino, Esq., LLC Urges Separated Parents to Plan Now for Thanksgiving, Christmas, and New Year's 2026-10-23 · PR Now · Banking, Legal https://pressreleasenews.org/pressroom/holiday-parenting-time-in-new-jersey-law-offices-of-sylvia-costantino-esq-llc-urges-separated-parents-to-plan-now-for-thanksgiving-christmas-and-new-years Red Bank family law firm offers practical guidance to help Monmouth, Ocean, and Middlesex County families reduce holiday custody conflict ———————————————————————————————————————————————————————————— Ahead of Veterans Day, San Antonio Military Divorce Attorney Explains What Happens to Retirement Pay, VA Disability, and Benefits in a Texas Divorce 2026-10-23 · PR Now · Legal https://pressreleasenews.org/pressroom/ahead-of-veterans-day-san-antonio-military-divorce-attorney-explains-what-happens-to-retirement-pay-va-disability-and-benefits-in-a-texas-divorce Joseph Lassen outlines the federal and Texas rules military families should understand before filing, from the 50 percent cap and the 10/10 rule to Howell v. Howell and the Survivor Benefit Plan and TRICARE deadlines. ———————————————————————————————————————————————————————————— Reel Fathers Rights Adds Senior Trial Attorney Victor Franco to Its Irvine Office, Serving Fathers Across Orange County and Los Angeles County 2026-10-23 · ACCESS Newswire · Real estate, Legal https://finance.yahoo.com/small-business/articles/reel-fathers-rights-adds-senior-005000607.html Franco Brings More Than a Decade of Family Law Trial Experience to Fathers Facing Custody, Restraining Order, and Property Division Disputes in Southern California CORONA, CA / October 22, 2026 / Reel Fathers Rights , the fastest growing law firm on the 2025 Inc. 5000 List of America's Fastest-Growing Pr ———————————————————————————————————————————————————————————— Build-A-Bear Investor News: If You Have Suffered Losses in Build-A-Bear Workshop, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights 2026-10-23 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/23/3387007/673/en/build-a-bear-investor-news-if-you-have-suffered-losses-in-build-a-bear-workshop-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html NEW YORK, Oct. 22, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Build-A-Bear Workshop, Inc. (NYSE: BBW) resulting from allegations that Build-A-Bear may have issued materially misleading business information to the investing public. ———————————————————————————————————————————————————————————— Quantum Law Group Founding Partners Jonathan Deer and Peyman Cohan Named 2026 Legal Visionaries 2026-10-22 · EIN Presswire · Legal https://www.einpresswire.com/article/951631818/quantum-law-group-founding-partners-jonathan-deer-and-peyman-cohan-named-2026-legal-visionaries Quantum Law Group Founding Partners Jonathan Deer and Peyman Cohan Named 2026 Legal Visionaries Recognition highlights their leadership in complex litigation, significant client results, and Quantum’s continued growth. Their ability to navigate complicated transactions, challenge powerful institutions, and pursue meaningful results is central to the work we do at Quantum.” — Steven Morris, Founding Partner BEVERLY HI ———————————————————————————————————————————————————————————— INV DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Innventure, Inc. Investors to Secure Counsel Before Important October 27 Deadline in Securities Class Action - INV 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386998/673/en/inv-deadline-notice-rosen-skilled-investor-counsel-encourages-innventure-inc-investors-to-secure-counsel-before-important-october-27-deadline-in-securities-class-action-inv.html NEW YORK, Oct. 22, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Innventure, Inc. (NASDAQ: INV) between November 17, 2025 and August 13, 2026, both dates inclusive (the “Class Period”), of the important October 27, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— QBTS INVESTOR DEADLINE: D-Wave Quantum Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - December 15, 2026 Deadline 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/qbts-investor-deadline-d-wave-quantum-inc-investors-with-substantial-losses-may-seek-to-lead-class-action-lawsuit-robbins-geller-rudman--dowd-llp-announces---december-15-2026-deadline-302916951.html SAN DIEGO, Oct. 22, 2026 -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of D-Wave Quantum Inc. (NASDAQ: QBTS) securities between February 26, 2026 and August 25, 2026, both dates inclusive (the "Class Period"), have until December 15, 2026 to seek... ———————————————————————————————————————————————————————————— ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages D-Wave Quantum Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – QBTS 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386993/673/en/rosen-highly-regarded-investor-counsel-encourages-d-wave-quantum-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-qbts.html NEW YORK, Oct. 22, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of D-Wave Quantum Inc. (NASDAQ: QBTS) between February 26, 2026 and August 25, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2026. ———————————————————————————————————————————————————————————— David Deane Law: Halloween and Holiday DUI Enforcement Raises the Stakes for Injury Crashes — Fairfax DUI Attorney Explains When a DUI Becomes a Felony 2026-10-22 · PR Now · Legal https://pressreleasenews.org/pressroom/david-deane-law-halloween-and-holiday-dui-enforcement-raises-the-stakes-for-injury-crashes-fairfax-dui-attorney-explains-when-a-dui-becomes-a-felony Fairfax DUI lawyer David Deane explains how a DUI crash that injures someone can turn a misdemeanor into a felony, just as Fairfax County enters its busiest stretch for impaired-driving enforcement. ———————————————————————————————————————————————————————————— TTMI SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES CLAIMS OF SECURITIES FRAUD AGAINST TTM TECHNOLOGIES, INC. 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/ttmi-shareholder-alert-ademi-llp-investigates-claims-of-securities-fraud-against-ttm-technologies-inc-302917437.html TTMI's stock recently dropped more than 25%; Ademi LLP is investigating TTM Technologies for potential securities fraud. CLICK HERE TO JOIN MILWAUKEE, Oct. 22, 2026 -- Ademi LLP is investigating possible securities fraud claims against TTM Technologies (Nasdaq: TTMI). The... ———————————————————————————————————————————————————————————— ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Gildan Activewear Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GIL 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386988/673/en/rosen-top-ranked-global-counsel-encourages-gildan-activewear-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-first-filed-by-the-firm-gil.html NEW YORK, Oct. 22, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Gildan Activewear Inc. (NYSE: GIL) between February 19, 2025 and June 15, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2026 in the securities class action first filed by the Firm. ———————————————————————————————————————————————————————————— Hagens Berman Issues Retraction of Public Statements Regarding University of Washington Sexual Assault Lawsuit 2026-10-22 · Business Wire · Education, Legal https://finance.yahoo.com/healthcare/articles/hagens-berman-issues-retraction-public-230000343.html SEATTLE, October 22, 2026--Attorneys at Hagens Berman issue a retraction regarding public statements made Oct. 13, 2026, concerning the firm's active sexual assault lawsuit against the University of Washington (UW). "Despite this retraction our lawsuit will proceed based on other theories of why we bel ———————————————————————————————————————————————————————————— MRP Investors Have Opportunity to Lead Millrose Properties, Inc. Securities Fraud Lawsuit 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/mrp-investors-have-opportunity-to-lead-millrose-properties-inc-securities-fraud-lawsuit-302917397.html NEW YORK, Oct. 22, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Millrose Properties, Inc. (NYSE: MRP) between February 7, 2025 and October 2, 2026, inclusive (the "Class Period"). A... ———————————————————————————————————————————————————————————— LINC Investors Have Opportunity to Lead Lincoln Educational Services Corporation Securities Fraud Lawsuit 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/linc-investors-have-opportunity-to-lead-lincoln-educational-services-corporation-securities-fraud-lawsuit-302917386.html NEW YORK, Oct. 22, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lincoln Educational Services Corporation (NASDAQ: LINC) between May 11, 2026 and August 9, 2026, inclusive (the "Class Period"), of the important November... ———————————————————————————————————————————————————————————— Kirby McInerney LLP Alerts Investors Who Acquired Honeywell Aerospace Inc. HONA Securities Between June 29, 2026 and September 1, 2026 of Pending Lawsuit 2026-10-22 · GlobeNewswire · Finance, Industrial, Aerospace & defense, Legal https://www.globenewswire.com/news-release/2026/10/22/3386974/937/en/kirby-mcinerney-llp-alerts-investors-who-acquired-honeywell-aerospace-inc-hona-securities-between-june-29-2026-and-september-1-2026-of-pending-lawsuit.html NEW YORK, Oct. 22, 2026 -- Kirby McInerney LLP reminds Honeywell Aerospace Inc. (“Honeywell Aerospace” or the “Company”) (NASDAQ: HONA) investors of the November 23, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. ———————————————————————————————————————————————————————————— HYLN DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Hyliion Holdings Corp. Investors to Secure Counsel Before Important October 27 Deadline in Securities Class Action - HYLN 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386970/673/en/hyln-deadline-notice-rosen-trusted-investor-counsel-encourages-hyliion-holdings-corp-investors-to-secure-counsel-before-important-october-27-deadline-in-securities-class-action-hyl.html NEW YORK, Oct. 22, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hyliion Holdings Corp. (NYSE American: HYLN) between May 12, 2026 and June 23, 2026, both dates inclusive (the “Class Period”), of the important October 27, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Sanjay Sukhdeo Marks First Year of Independent Practice as The Lambo Lawyer 2026-10-22 · ACCESS Newswire · Legal https://finance.yahoo.com/small-business/articles/sanjay-sukhdeo-marks-first-independent-213500146.html NEW YORK CITY, NY / October 22, 2026 / Sanjay Sukhdeo , founder of The Law Office of Sanjay Sukhdeo Law Firm in New York and the criminal defense attorney known as " The Lambo Lawyer ," is marking one year since opening his own practice, bringing his background as a prosecutor to an approach centered on ———————————————————————————————————————————————————————————— QFIN Investors Have Rights - If You Lost Money Investing in Qfin Holdings, Inc. Contact Robbins LLP for Information About Recovering Your Losses 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/qfin-investors-have-rights--if-you-lost-money-investing-in-qfin-holdings-inc-contact-robbins-llp-for-information-about-recovering-your-losses-302917278.html SAN DIEGO, Oct. 22, 2026 -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Qfin Holdings, Inc. (NASDAQ: QFIN) securities between March 18, 2026 and August 25, 2026,... ———————————————————————————————————————————————————————————— QBTS Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the D-Wave Quantum Inc. Class Action Lawsuit 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386966/32719/en/qbts-class-action-reminder-robbins-llp-reminds-investors-of-the-lead-plaintiff-deadline-in-the-d-wave-quantum-inc-class-action-lawsuit.html Robbins LLP is investigating allegations that D-Wave Quantum Inc. (QBTS) overstated its business and financial prospects. ———————————————————————————————————————————————————————————— Nearly $28 Million Settlement Reached for Former Essex Tenants Across California Regarding Security Deposit 2026-10-22 · EIN Presswire · Real estate, Legal https://www.einpresswire.com/article/951598254/nearly-28-million-settlement-reached-for-former-essex-tenants-across-california-regarding-security-deposit San Diego, California — Former residents of Essex Property Trust apartment communities throughout California will benefit from a proposed class action settlement valued at approximately $27.95 million, along with meaningful improvements to how security deposits are handled going forward. The settlement resolves Norman, et al. v. Essex Property Trust, Inc., et al. , San Diego Superior Court Case No. 37-2022-00038519-C ———————————————————————————————————————————————————————————— NVEC INVESTIGATION: NVE Corp. Investors Should Contact Block & Leviton to Possibly Recover Losses 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386965/23044/en/nvec-investigation-nve-corp-investors-should-contact-block-leviton-to-possibly-recover-losses.html Block & Leviton is investigating NVE Corp. (NVEC) for possible securities fraud. Investors should contact the firm to recover losses. ———————————————————————————————————————————————————————————— ROSEN, A LEADING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386961/673/en/rosen-a-leading-law-firm-encourages-doximity-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-docs.html NEW YORK, Oct. 22, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between August 8, 2024 and May 13, 2026, both dates inclusive (the “Class Period”), of the important November 16, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Mark Pierce Discusses Protecting Wealth Before Building It on the Wealth B-Hers Podcast 2026-10-22 · EIN Presswire · Media, Legal https://www.einpresswire.com/article/947531530/mark-pierce-discusses-protecting-wealth-before-building-it-on-the-wealth-b-hers-podcast I’ve never had anyone say they wish they hadn’t gotten into the trust...The only thing I’ve ever heard a client say is that I wished I’d gotten into the trust sooner.” — Mark Pierce WY, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Asset protection attorney explains how LLCs, trusts and proactive planning can help safeguard growing wealth from financial risks. Waiting until significant wealth has been accum ———————————————————————————————————————————————————————————— Mark Pierce Shares Wealth Protection Moves Business Owners Miss on The Practical Wealth Show 2026-10-22 · EIN Presswire · Crypto, Legal https://www.einpresswire.com/article/947530583/mark-pierce-shares-wealth-protection-moves-business-owners-miss-on-the-practical-wealth-show If you’ve got an asset protection trust and you’re treating it like your back pocket and use it as a wallet anytime you need it for personal expenses, then you don’t respect the existence of the trust” — Mark Pierce WY, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Asset protection attorney discusses trusts, LLCs, lawsuits, divorce and the mistakes that can leave business owners exposed. Business owners spe ———————————————————————————————————————————————————————————— Legal vs. Illegal Insider Trading: What's the Difference? | Wichita Criminal Defense Lawyers 2026-10-22 · PR Newswire · Legal https://www.prnewswire.com/news-releases/legal-vs-illegal-insider-trading-whats-the-difference--wichita-criminal-defense-lawyers-302917452.html WICHITA, Kan., Oct. 22, 2026 -- You've probably heard "insider trading" used to describe a serious financial crime. But here's something you may not know: not all insider trading is illegal. The difference often comes down to what information a person had and how it was... ———————————————————————————————————————————————————————————— BC's New Prompt Payment Law May Face Resistance From Contractors It Aims to Protect, Says Vancouver Lawyer 2026-10-22 · EIN Presswire · Legal, Construction & engineering https://www.einpresswire.com/article/951308800/bc-s-new-prompt-payment-law-may-face-resistance-from-contractors-it-aims-to-protect-says-vancouver-lawyer Ada P. Lam, principal lawyer at Lam Legal - Trial Lawyers, discusses the potential challenges facing BC contractors under the province's new Construction Prompt Payment Act. Lam Legal's Ada P. Lam says stronger payment protections could benefit BC contractors, but long-standing industry relationships may make enforcement difficult. If that developer is late making a payment, the subcontractor has to decide whether pu ———————————————————————————————————————————————————————————— Nano-X Imaging (NNOX) Advances Its Mission to Expand Access to Medical Imaging 2026-10-22 · NewMediaWire · Finance, AI, SaaS, Healthcare, Media, Legal, Jobs & workplace, Medical devices https://www.newmediawire.com/news/nano-x-imaging-nnox-advances-its-mission-to-expand-access-to-medical-imaging-7090818 Nanox is working to make advanced medical imaging more accessible through digital 3D tomosynthesis technology designed to enhance visualization beyond conventional X-rays. Its Nanox.ARC platform combines imaging hardware with cloud-based infrastructure, while the company’s broader services support image interpretation and clinical workflows. By connecting image acquisition with remote radiology expertise and AI-powered analysis, Nanox aims to support healthcare providers’ imaging and interpretation workflows more efficiently. LOS ANGELES, CA - October 22, 2026 - Access to medical imaging remains an important consideration for healthcare systems, particularly in underserved regions where equipment, infrastructure and trained personnel may be limited. While conventional X-rays play an essential role in diagnostic care, their two-dimensional images can make certain anatomical details more difficult to distinguish when structures overlap. In some healthcare settings, rising imaging volumes and radiologist workforce constraints can also place pressure on diagnostic services. These challenges underscore the importance of developing imaging technologies that can complement existing diagnostic approaches while integrating into established clinical environments and workflows. Nano-X Imaging (NASDAQ: NNOX) is approaching that problem from a different direction. Nanox is assembling an integrated platform intended to extend medical imaging into outpatient facilities, clinics and other settings where conventional advanced… Read More Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— Mobilicom (MOB) Targets Growing Drone and Robotics Market With Cybersecure Technology Portfolio 2026-10-22 · NewMediaWire · Finance, AI, Media, Aerospace & defense, Cybersecurity, Legal, Software & IT https://www.newmediawire.com/news/mobilicom-mob-targets-growing-drone-and-robotics-market-with-cybersecure-technology-portfolio-7090817 Mobilicom provides integrated cybersecure hardware and software solutions for defense and commercial drones, robotics and autonomous systems. Its technologies are designed to support mission-critical communications, reliable connectivity and protection against electronic interference and cyber threats. The recent launch of the SwarmiX family expands Mobilicom’s portfolio with high-throughput mesh communications designed for coordinated drones and robotic fleets. LOS ANGELES, CA - October 22, 2026 - As defense organizations and commercial operators expand their use of unmanned systems, the technologies that keep these platforms connected, secure and operational are becoming increasingly important. Mobilicom (NASDAQ: MOB) addresses these needs through an integrated portfolio of cybersecurity, software and hardware designed for drones, robotics and other autonomous platforms operating in demanding environments. The company primarily serves original equipment manufacturers (“OEMs”) developing unmanned platforms for applications where reliable communications and system resilience are essential. Its solutions address several core requirements of autonomous operations, including secure data transmission, robust connectivity and protection against cyber threats and… Read More Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to MOB are available in the company’s newsroom at https://ibn.fm/MOB Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— DEADLINE ALERT for Innventure, Inc. (INV), XTI Aerospace, Inc. (XTIA), Flotek Industries, Inc. (FTK), and Baidu, Inc. (BIDU): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions 2026-10-22 · GlobeNewswire · Aerospace & defense, Legal, Internet & apps https://www.globenewswire.com/news-release/2026/10/22/3386841/3448/en/deadline-alert-for-innventure-inc-inv-xti-aerospace-inc-xtia-flotek-industries-inc-ftk-and-baidu-inc-bidu-the-law-offices-of-howard-g-smith-reminds-investors-of-opportunity-to-lead.html Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Innventure, Inc., XTI Aerospace, Inc., Flotek Industries, Inc., and Baidu, Inc. Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Innventure, Inc., XTI Aerospace, Inc., Flotek Industries, Inc., and Baidu, Inc. ———————————————————————————————————————————————————————————— FUN Shareholder Investigation - Robbins LLP is Investigating the Officers and Directors of FUN for Violations of Securities Laws and Breaches of Fiduciary Duty 2026-10-22 · PR Newswire · Finance, Legal, Entertainment https://www.prnewswire.com/news-releases/fun-shareholder-investigation---robbins-llp-is-investigating-the-officers-and-directors-of-fun-for-violations-of-securities-laws-and-breaches-of-fiduciary-duty-302917257.html SAN DIEGO, Oct. 22, 2026 -- Shareholder rights law firm Robbins LLP is investigating Six Flags Entertainment Corporation (NYSE: FUN) to determine whether certain Six Flag's officers and directors violated securities laws and breached fiduciary duties to shareholders. Six... ———————————————————————————————————————————————————————————— Jacksonville Tax Attorneys at J. David Tax Law Return as Hero Sponsor of the Dreams Come True 5K 2026-10-22 · EIN Presswire · Legal https://www.einpresswire.com/article/951572123/jacksonville-tax-attorneys-at-j-david-tax-law-return-as-hero-sponsor-of-the-dreams-come-true-5k J. David Tax Law J David Tax Law at the Dreams Come True 5k The J David Tax Law team Tax law firm in Jacksonville, FL fields an employee team at the 2026 Dreams Come True 5K Walk, supporting local children with life-threatening illnesses. Our clients come to us at some of the hardest moments of their lives, and we know what it means to have someone in your corner.” — Jonathan Sooriash JACKSONVILLE, FL, UNITED STATES, ———————————————————————————————————————————————————————————— Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386840/35454/en/beta-bionics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-beta-bionics-inc-bbnx.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX), if they purchased or otherwise acquired the Company’s common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California. ———————————————————————————————————————————————————————————— Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS 2026-10-22 · GlobeNewswire · Finance, Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/22/3386839/35454/en/hims-hers-health-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-hims-hers-health-inc-hi.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the Company’s securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California. ———————————————————————————————————————————————————————————— Chemours Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Chemours Company - CC 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386836/35454/en/chemours-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-the-chemours-company-cc.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware. ———————————————————————————————————————————————————————————— Honeywell Aerospace Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Honeywell Aerospace, Inc. - HONA 2026-10-22 · GlobeNewswire · Industrial, Aerospace & defense, Legal https://www.globenewswire.com/news-release/2026/10/22/3386834/35454/en/honeywell-aerospace-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-honeywell-aerospace-.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against Honeywell Aerospace, Inc. (“Honeywell Aerospace” or the “Company”) (NasdaqGS: HONA), if they purchased Honeywell Aerospace, Inc. shares on the open market between June 29, 2026 and September 1, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Arizona. ———————————————————————————————————————————————————————————— Duolingo Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Duolingo, Inc. - DUOL 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386832/35454/en/duolingo-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-duolingo-inc-duol.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against Duolingo, Inc. (“Duolingo” or the “Company”) (NasdaqGS: DUOL), if they purchased Duolingo, Inc. Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania. ———————————————————————————————————————————————————————————— ROSEN, SKILLED INVESTOR COUNSEL, Encourages Coastal Financial Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CCB 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386831/673/en/rosen-skilled-investor-counsel-encourages-coastal-financial-corporation-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-ccb.html NEW YORK, Oct. 22, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Coastal Financial Corporation (NASDAQ: CCB) between October 28, 2024 and July 29, 2026, inclusive (the “Class Period”), of the important December 1, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— What Does York Space Systems, Inc.'s 70% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/what-does-york-space-systems-incs-70-stock-drop-mean-for-investors-the-law-offices-of-howard-g-smith-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302916956.html Suit alleges York Space Systems, Inc. failed to disclose key facts to investors from January 29, 2026 through May 11, 2026; lead plaintiff deadline is October 30, 2026 BENSALEM, Pa., Oct. 22, 2026 -- The Law Offices of Howard G. Smith today reported that a securities class... ———————————————————————————————————————————————————————————— Ensign Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Ensign Group, Inc. - ENSG 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386828/35454/en/ensign-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-the-ensign-group-inc-ensg.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Ensign Group, Inc. (“Ensign” or the “Company”) (NasdaqGS: ENSG), if they purchased or otherwise acquired The Ensign Group, Inc. securities between February 10, 2022 and June 18, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California. ———————————————————————————————————————————————————————————— York Space Systems Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against York Space Systems, Inc. - YSS 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386826/35454/en/york-space-systems-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-york-space-systems-in.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against York Space Systems, Inc. (“York Space Systems” or the “Company”) (NYSE: YSS), if they purchased or otherwise acquired (a) York Space Systems common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s January 2026 initial public offering (“IPO” or the “Offering”); and/or (b) securities between January 29, 2026 and May 11, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Colorado. ———————————————————————————————————————————————————————————— What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-22 · PR Newswire · Finance, Biotech & pharma, Legal https://www.prnewswire.com/news-releases/what-does-unicycive-therapeutics-incs-39-1-stock-drop-mean-for-investors-the-law-offices-of-howard-g-smith-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302916947.html Suit alleges Unicycive Therapeutics, Inc. failed to disclose key facts to investors from December 29, 2025 through June 29, 2026; lead plaintiff deadline is November 2, 2026 BENSALEM TOWNSHIP, Pa., Oct. 22, 2026 -- The Law Offices of Howard G. Smith today reported that a... ———————————————————————————————————————————————————————————— Millrose Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Millrose Properties, Inc. - MRP 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386825/35454/en/millrose-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-millrose-properties-inc-mrp.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 8, 2026 to file lead plaintiff applications in a securities class action lawsuit against Millrose Properties, Inc. (“Millrose” or the “Company”) (NYSE: MRP), if they purchased or otherwise acquired Millrose Properties, Inc. securities between February 7, 2025 and October 2, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Florida. ———————————————————————————————————————————————————————————— One in Five Top-Ranking Law Firms Is Almost Entirely AI-Generated, Even After Google’s September Spam Update 2026-10-22 · EIN Presswire · AI, SaaS, Media, Legal, Marketing & advertising https://www.einpresswire.com/article/951551769/one-in-five-top-ranking-law-firms-is-almost-entirely-ai-generated-even-after-google-s-september-spam-update San Francisco, California – Custom Legal Marketing (CLM), the law firm marketing agency behind Sequoia, the AI marketing platform for lawyers, released its largest study to date on AI content and law firm rankings . The study scored every law firm page ranking in the top eight Google results for 26 competitive legal searches across 93 U.S. metropolitan areas, 2,418 queries in all, eight days after the September 2026 ———————————————————————————————————————————————————————————— What's Next for Hyliion Holdings Corp. Shareholders After 19.3% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/whats-next-for-hyliion-holdings-corp-shareholders-after-19-3-stock-drop-glancy-prongay-wolke--rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline-302916877.html Complaint alleges Hyliion Holdings Corp. misled investors between May 12, 2026 and June 23, 2026; investors may seek lead plaintiff role by October 27, 2026 LOS ANGELES, Oct. 22, 2026 -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action... ———————————————————————————————————————————————————————————— CMCT Investor Losses: KT Files $500K Case Against Osaic Wealth 2026-10-22 · EIN Presswire · Legal https://www.einpresswire.com/article/951501326/cmct-investor-losses-kt-files-500k-case-against-osaic-wealth Claim Alleges Former Triad Advisors Broker Joey Cason Recommended Illiquid CMCT to Retired Investors ATLANTA, GA, UNITED STATES, October 22, 2026 / EINPresswire.com / -- National investment loss and securities law firm KlaymanToskes announces the filing of a Financial Industry Regulatory Authority (“FINRA”) arbitration claim against Osaic Wealth, Inc., as successor-in-interest to Triad Advisors, LLC. The claim, FINRA ———————————————————————————————————————————————————————————— Rosen Law Firm Encourages Fervo Energy Company Investors to Inquire About Securities Class Action Investigation - FRVO 2026-10-22 · PR Newswire · Finance, Energy, Legal https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-fervo-energy-company-investors-to-inquire-about-securities-class-action-investigation---frvo-302917191.html NEW YORK, Oct. 22, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Fervo Energy Company (NASDAQ: FRVO) resulting from allegations that Fervo Energy may have issued materially... ———————————————————————————————————————————————————————————— Todd J. Leonard Law Firm Announces $840,000 Settlement in Morris County Truck Crash Case 2026-10-22 · EIN Presswire · Automotive, Legal https://www.einpresswire.com/article/951551830/todd-j-leonard-law-firm-announces-840-000-settlement-in-morris-county-truck-crash-case Denville, New Jersey – The Todd J. Leonard Law Firm has announced an $840,000 settlement in a truck accident lawsuit pending in the Superior Court of New Jersey, Law Division, Morris County, resolving claims brought by a woman who suffered serious spinal injuries after a dump truck crashed into her car. According to the firm, the collision left the plaintiff with significant spinal trauma that required multiple surge ———————————————————————————————————————————————————————————— Could Pennsylvania's 50/50 Custody Bill Change How Courts Decide Parenting Time? 2026-10-22 · EIN Presswire · Legal https://www.einpresswire.com/article/951561291/could-pennsylvania-s-50-50-custody-bill-change-how-courts-decide-parenting-time Attorneys Beth Tibbott and Dana Richardson of TIbbott & Richardson, P.C. highlight how custody decisions and parenting time in Pennsylvania may be affected by HB 1499. Tibbott & Richardson, P.C. Explains How Pennsylvania's Proposed HB 1499 Could Change the Starting Point for Child Custody and Parenting Time Decisions Custody decisions affect much more than a court schedule. They affect how parents and children mainta ———————————————————————————————————————————————————————————— What Should Gildan Activewear Inc. Investors Know After 18.8% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/what-should-gildan-activewear-inc-investors-know-after-18-8-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302916870.html Lawsuit alleges Gildan Activewear Inc. made misleading statements to investors from February 19, 2025 to June 15, 2026; lead plaintiff motions are due December 14, 2026 LOS ANGELES, Oct. 22, 2026 -- The Law Offices of Frank R. Cruz today announced a class action lawsuit... ———————————————————————————————————————————————————————————— Kaplan Fox & Kilsheimer LLP Alerts Gildan Activewear Inc. (NYSE: GIL) Investors to a Securities Class Action Deadline on December 14, 2026 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386804/1020/en/kaplan-fox-kilsheimer-llp-alerts-gildan-activewear-inc-nyse-gil-investors-to-a-securities-class-action-deadline-on-december-14-2026.html Kaplan Fox announces a securities class action against Gildan Activewear (NYSE: GIL) for investors from Feb. 19, 2025 to June 15, 2026. ———————————————————————————————————————————————————————————— St. Louis Personal Injury Firm Reports Higher Initial Offers and 87% Faster Medical Record Review Using EvenUp 2026-10-22 · Business Wire · AI, SaaS, Healthcare, Insurance, Legal https://finance.yahoo.com/technology/ai/articles/st-louis-personal-injury-firm-172100854.html Holland Injury Law says EvenUp's AI platform cut up to 30 hours from complex demands and put stronger cases in front of insurers ST. LOUIS, Mo., October 22, 2026--A medical review that once took Holland Injury Law's attorneys a couple of hours now takes about 15 minutes. The St. Louis trial firm credits EvenUp's AI platform, and says the gains extend to the negotiating table: higher initial offers ———————————————————————————————————————————————————————————— What Should Fluence Energy, Inc. Investors Know After 34.63% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-22 · PR Newswire · Finance, Energy, Legal https://www.prnewswire.com/news-releases/what-should-fluence-energy-inc-investors-know-after-34-63-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302916785.html Lawsuit alleges Fluence Energy, Inc. made misleading statements to investors from November 24, 2025 to September 16, 2026; lead plaintiff motions are due November 30, 2026 LOS ANGELES, Oct. 22, 2026 -- The Law Offices of Frank R. Cruz today announced a class action lawsuit... ———————————————————————————————————————————————————————————— Clarus Founder Niosha Shakoori Discusses Emerging Workplace Hate Speech Legislation at 2026 California HR Conference 2026-10-22 · PR Newswire · Legal, Government & policy, Jobs & workplace https://www.prnewswire.com/news-releases/clarus-founder-niosha-shakoori-discusses-emerging-workplace-hate-speech-legislation-at-2026-california-hr-conference-302916770.html NEWPORT BEACH, Calif., Oct. 22, 2026 -- Clarus, a boutique woman-owned California employment law firm specializing in management-side workplace counsel, HR compliance, and objective workplace investigations, is pleased to announce that Founder and Managing Partner Niosha... ———————————————————————————————————————————————————————————— What Should Anavex Life Sciences Corp. Investors Know After 6.35% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/what-should-anavex-life-sciences-corp-investors-know-after-6-35-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302916630.html Lawsuit alleges Anavex Life Sciences Corp. made misleading statements to investors from November 26, 2025 to August 28, 2026; lead plaintiff motions are due November 30, 2026 LOS ANGELES, Oct. 22, 2026 -- The Law Offices of Frank R. Cruz today announced a class action lawsuit... ———————————————————————————————————————————————————————————— SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Better Home & Finance Holding Company (NASDAQ: BETR) — Investors Who Suffered Losses Are Encouraged to Contact the Firm 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3386783/9788/en/shareholder-alert-bronstein-gewirtz-grossman-llc-announces-class-action-against-better-home-finance-holding-company-nasdaq-betr-investors-who-suffered-losses-are-encouraged-to-cont.html New class action for Better Home & Finance urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/20/2026 ———————————————————————————————————————————————————————————— SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Bank of America Corporation (NYSE: BAC) — Investors Who Suffered Losses Are Encouraged to Contact the Firm 2026-10-22 · GlobeNewswire · Finance, Banking, Legal https://www.globenewswire.com/news-release/2026/10/22/3386780/9788/en/shareholder-alert-bronstein-gewirtz-grossman-llc-announces-class-action-against-bank-of-america-corporation-nyse-bac-investors-who-suffered-losses-are-encouraged-to-contact-the-fir.html New class action for Bank of America (BAC) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 12/15/2026 ———————————————————————————————————————————————————————————— Attorney, Author, Entrepreneur, and The IRS Angel Yael N. Lazar of EMBER Recently Featured on Close Up Radio 2026-10-22 · EIN Presswire · Real estate, Legal https://www.einpresswire.com/article/951536374/attorney-author-entrepreneur-and-the-irs-angel-yael-n-lazar-of-ember-recently-featured-on-close-up-radio LOCUST VALLEY, NY, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Yael Lazar is an attorney, author, entrepreneur, and founder of EMBER. Over more than three decades, her legal career has included matrimonial law earlier in her career, as well as tax matters and IRS controversy, estate planning, and real estate. She stopped practicing matrimonial law more than 15 years ago. Yael is also affectionately known ———————————————————————————————————————————————————————————— Six Major MLS Organizations Sue Compass to Protect Equal Access to Home Listings 2026-10-22 · PR Newswire · Real estate, Legal https://www.prnewswire.com/news-releases/six-major-mls-organizations-sue-compass-to-protect-equal-access-to-home-listings-302917228.html Joint lawsuit filed by Robinson Bradshaw seeks to uphold rules that protect brokers, agents, and consumers. NEW YORK, Oct. 22, 2026 -- Six major multiple listing services (MLSs) representing more than 120,000 real estate professionals nationwide have filed a joint federal... ———————————————————————————————————————————————————————————— DEADLINE ALERT for DKS, BBNX, FCEL, and LINC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386736/0/en/deadline-alert-for-dks-bbnx-fcel-and-linc-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-actions-on-behalf-of-shareholders.html LOS ANGELES, Oct. 22, 2026 -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion. ———————————————————————————————————————————————————————————— DEADLINE ALERT for HONA and TYGO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386735/0/en/deadline-alert-for-hona-and-tygo-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-actions-on-behalf-of-shareholders.html LOS ANGELES, Oct. 22, 2026 -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. ———————————————————————————————————————————————————————————— Faruqi & Faruqi, LLP Urges York Space Systems Inc. (NYSE: YSS) Investors to Seek Counsel Before the October 30, 2026 Lead Plaintiff Deadline in the Securities Class Action 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/faruqi--faruqi-llp-urges-york-space-systems-inc-nyse-yss-investors-to-seek-counsel-before-the-october-30-2026-lead-plaintiff-deadline-in-the-securities-class-action-302916629.html Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in York Space Systems to Contact Him Directly to Discuss Their Options NEW YORK, Oct. 22, 2026 -- Faruqi & Faruqi, LLP, a leading national securities law firm,... ———————————————————————————————————————————————————————————— Faruqi & Faruqi, LLP Urges XTI Aerospace, Inc. (NASDAQ: XTIA) Investors to Seek Counsel Before the October 27, 2026 Lead Plaintiff Deadline in the Securities Class Action 2026-10-22 · PR Newswire · Finance, Aerospace & defense, Legal https://www.prnewswire.com/news-releases/faruqi--faruqi-llp-urges-xti-aerospace-inc-nasdaq-xtia-investors-to-seek-counsel-before-the-october-27-2026-lead-plaintiff-deadline-in-the-securities-class-action-302916631.html Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in XTI Aerospace to Contact Him Directly to Discuss Their Options NEW YORK, Oct. 22, 2026 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds... ———————————————————————————————————————————————————————————— BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386664/0/en/bbnx-investor-alert-schall-brown-schwartz-llp-files-class-action-lawsuit-against-beta-bionics-inc-and-announces-opportunity-for-investors-to-lead-class-action-lawsuit.html BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Cla ———————————————————————————————————————————————————————————— Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386651/9788/en/bronstein-gewirtz-grossman-llc-urges-ardelyx-inc-investors-to-act-class-action-filed-alleging-investor-harm.html New class action for Ardelyx, Inc. (ARDX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/16/2026 ———————————————————————————————————————————————————————————— Hicks Thomas Partner Stewart Hoffer Named to Listing of the Nation’s Top Corporate Employment Lawyers 2026-10-22 · Business Wire · Legal https://finance.yahoo.com/small-business/articles/hicks-thomas-partner-stewart-hoffer-145800073.html Mr. Hoffer recognized by Lawdragon for a fifth year HOUSTON, October 22, 2026--Hicks Thomas partner Stewart E. Hoffer , a familiar name in the complex realm of labor and employment litigation, has earned another year's recognition among the nation's best with his selection to the 2027 Lawdragon 500 Leading Corporate Employment Lawyers legal guide. Lawdragon said its honorees "advise companies larg ———————————————————————————————————————————————————————————— Coca-Cola Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed 2026-10-22 · GlobeNewswire · Cybersecurity, Legal https://www.globenewswire.com/news-release/2026/10/22/3386598/0/en/coca-cola-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-customer-data-is-exposed.html delson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a reported data breach at Coca-Cola. ———————————————————————————————————————————————————————————— CELH Investors Have Opportunity to Lead Celsius Holdings, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386592/0/en/celh-investors-have-opportunity-to-lead-celsius-holdings-inc-securities-fraud-lawsuit-with-sbs-law.html CELH Investors Have Opportunity to Lead Celsius Holdings, Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— YSS Investors Have Opportunity to Lead York Space Systems, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386589/0/en/yss-investors-have-opportunity-to-lead-york-space-systems-inc-securities-fraud-lawsuit-with-sbs-law.html YSS Investors Have Opportunity to Lead York Space Systems, Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— INV Investors Have Opportunity to Lead Innventure, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-22 · GlobeNewswire · Legal https://www.globenewswire.com/news-release/2026/10/22/3386583/0/en/inv-investors-have-opportunity-to-lead-innventure-inc-securities-fraud-lawsuit-with-sbs-law.html INV Investors Have Opportunity to Lead Innventure, Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— Trial Lawyer Daniel J. Voelker Releases "Shaken, Not Stirred: A Gentleman's Guide to Living Like Bond," Available on Amazon October 22, 2026 2026-10-22 · PR.com · Retail, Legal, Entertainment https://www.pr.com/press-release/982544 Drawing on Ian Fleming's original novels rather than the films, "Shaken, Not Stirred" translates what Bond does well into things any reader can do himself, starting the same day. "Bond was a fictional spy," Voelker writes. "The poise he carried is real, and it is available to anyone willing to learn it. "As a trial lawyer, my job is to read a room, size up the opposition and keep my composure when everything is on the [PR.com] ———————————————————————————————————————————————————————————— Ifrah Law Significantly Expands Online Gaming Talent 2026-10-22 · Business Wire · Gaming, Legal https://finance.yahoo.com/small-business/articles/ifrah-law-significantly-expands-online-140000251.html Six New "Gamechangers" Deepen Firm's Bench as Demand Increases for Sophisticated iGaming Counsel WASHINGTON, October 22, 2026--Ifrah Law, a leading law firm serving the U.S. iGaming industry , announced a significant expansion of its team with the addition of six professionals. The new "Gamechangers" d ———————————————————————————————————————————————————————————— Haber Law Strengthens Real Estate Practice Adding Will Prince as Partner 2026-10-22 · Business Wire · Real estate, Banking, Legal https://finance.yahoo.com/real-estate/articles/haber-law-strengthens-real-estate-140000715.html Prince brings more than 20 years of experience advising developers, investors, family offices, and lenders on complex real estate transactions MIAMI, October 22, 2026--Haber Law today announced that prominent real estate attorney Will Prince has joined the Firm as a Partner, bolstering its real estate ———————————————————————————————————————————————————————————— Goodwin Launches AI Governance Program to Help Companies Accelerate AI Adoption 2026-10-22 · Business Wire · AI, Investing & markets, Legal https://finance.yahoo.com/technology/ai/articles/goodwin-launches-ai-governance-program-140000198.html Legal tech offering puts the firm's judgment and breadth of expertise at the fingertips of companies, boards, and private equity sponsors NEW YORK & LOS ANGELES, October 22, 2026--Global law firm Goodwin today announced Goodwin AI Governance, a multi-pronged program that supports organizations working ———————————————————————————————————————————————————————————— Management Executes Third Open Market Share Purchase as SNRY Transition Wraps Up and Company Targets $100M+ Synergistic Powerhouse 2026-10-22 · NewMediaWire · Finance, SaaS, Energy, Legal https://www.newmediawire.com/news/management-executes-third-open-market-share-purchase-as-snry-transition-wraps-up-and-company-targets-100m+-synergistic-powerhouse-7090797 BLOOMINGTON, MN - October 22, 2026 - Solar Energy Initiatives, Inc. (OTC: SNRY) today issued a shareholder update following the appointment of Derrick Whitehead as President and Chief Executive Officer earlier this month. The Company is completing the final housekeeping items associated with the management transition and is now positioned to accelerate its strategic shift into a shareholder first holding company, incubator, and launch platform. With transition related work nearly finished, management is focused on execution. Derrick Whitehead will look to contribute companies from his current holdings to the SNRY platform, alongside other joint-venture partners and qualified private companies that are interested in going public. The objective is to assemble multiple operating businesses that generate real activity and revenue while creating meaningful synergies with one another under the SNRY structure. The Company has set a clear goal of reaching a $100+ million market capitalization in 2027 and building a genuine powerhouse rather than a single asset story. This multi-company approach is designed so that the businesses reinforce each other, strengthen the overall balance sheet, and create durable value for existing shareholders. “We are wrapping up the remaining transition housekeeping so we can move forward cleanly and with focus,” said Derrick Whitehead, President and Chief Executive Officer of SNRY. “My priority remains protecting existing shareholders while bringing real assets, operators, and non-toxic capital onto the platform. We intend to build something shareholders can be proud of, an outcome that has been too rare on the OTC.” Management continues to demonstrate its belief in SNRY’s future through its third open-market purchase of shares. These purchases, made with management’s own capital, reflect continued confidence in the Company’s direction and capital structure. The Company thanks shareholders for their continued patience while the structure is put in place to protect holders for the long term. Protecting the existing shareholder base remains a non-negotiable priority as SNRY evaluates opportunities, partners, and capital. Further updates will be provided as specific companies, joint ventures, and other initiatives are advanced and as additional details become available. About Solar Energy Initiatives, Inc. Solar Energy Initiatives, Inc. (OTC: SNRY) is pivoting to operate as a shareholder-first holding company, incubator, and launch pad. The Company is pursuing multiple acquisitions and partnerships designed to add real assets, activity, and revenue to the balance sheet while maintaining a capital structure built to protect existing shareholders. More information is available at the Company’s OTC Markets page. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s goals for market capitalization, potential acquisitions, joint ventures, partnerships, capital structure, and future operations. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. The Company undertakes no obligation to update these statements except as required by law. Contact Investor Relations Solar Energy Initiatives, Inc. derrick123@nym.hush.com ———————————————————————————————————————————————————————————— Uganda: Justice Ministry and Director of Public Prosecutions (DPP) on spot over diversion of Shs41 billion 2026-10-22 · APO Group · SaaS, Legal, Government & policy, Jobs & workplace https://www.africa-newsroom.com/press/uganda-justice-ministry-and-director-of-public-prosecutions-dpp-on-spot-over-diversion-of-shs41-billion?lang=en The Public Accounts Committee (Central Government) has criticised the Ministry of Justice and Constitutional Affairs, and the Office of the Director of Public Prosecutions (ODPP) for diverting Shs41.6 billion to activities outside their approved work plans. This, according to the Committee, was done without authorisation by the Minister of Finance, Planning and Economic Development, Hon. Henry Musasizi. The committee, chaired by Kassanda North MP, Hon. Patrick Nsamba, said the expenditure contravened provisions of the Public Finance Management Act. The findings are contained in the committee’s report on the Auditor General’s audit for the year ended December 2025, presented during plenary sitting chaired by Deputy Speaker, Thomas Tayebwa on Wednesday, 21 October 2026. “The two entities applied a combined Shs41.6 billion to items that Parliament had not appropriated, without evidence of the Minister’s authorisation,” Nsamba said. The ODPP spent Shs900 million on constructing Resident State Attorney offices in Katakwi and Yumbe outside its approved work plan, while the ministry of Justice diverted Shs40.7 billion. “Savings on a budget line do not confer authority to spend on activities outside the approved work plan,” Nsamba said. According to the committee, a big amount of the money was spent on court awards and compensation. The report noted that the ODPP had filled only 600 of its 1,704 approved positions, leaving 399 prosecutors serving 149 field stations to handle heavy workloads, adding that out of 40,501 new cases received, only 23,184 were committed for High Court trial. The committee also questioned the procurement of works worth Shs457.68 million for the Yumbe office outside the electronic government procurement system. The committee report further raised concern over the malfunctioned Prosecution Case Management Information System (PROCAMIS), despite a Shs42 billion expenditure, since 2017. Nsamba added that the ODPP paid Shs2.95 billion to M/s Graphics Systems for maintenance and support in 2024/2025, but key deliverables, including integration with other criminal justice institutions and an off-site disaster recovery facility, were not provided. “Shillings 2.95 billion was paid under a contract whose two principal deliverables were not provided and the liability clause was not invoked against the provider,” he said. The committee recommended enforcing the contract’s liability provisions, recovering warranted funds, establishing disaster recovery arrangements and auditing the system. The Committee’s findings also revealed that infrastructure in Arua and Lira had remained idle since November 2022. Nsamba said that the ministry of Justice reported contingent liabilities of Shs3.492 trillion, largely arising from lawsuits against government entities. The committee recommended a litigation management strategy to improve tracking and management of claims. The Committee also called for stronger financial accountability, improved staffing, functional digital systems and tighter oversight of public expenditure. Distributed by APO Group on behalf of Parliament of the Republic of Uganda. ———————————————————————————————————————————————————————————— Influential Women Highlights Georgina Silva: Bridging Law, Business Intelligence, And Strategy For Organizational Growth 2026-10-22 · EIN Presswire · Legal https://www.einpresswire.com/article/951501343/influential-women-highlights-georgina-silva-bridging-law-business-intelligence-and-strategy-for-organizational-growth ORLANDO, FL, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Business Intelligence Expert and Creator of the SILVA-BI Method Brings More Than 15 Years of International Experience to Business Consulting, Legal Strategy, and Entrepreneurship Orlando, Florida – Georgina Silva is a bilingual business intelligence expert, entrepreneur, published author, Venezuelan attorney, and international business strategist wh ———————————————————————————————————————————————————————————— Notaron Becomes the First Online Notary Platform Available to Smokeball Users 2026-10-22 · PR Now · SaaS, Legal https://pressreleasenews.org/pressroom/notaron-becomes-the-first-online-notary-platform-available-to-smokeball-users-2 New integration lets law firms manage online notarizations from inside a Smokeball matter — with live, state-commissioned notaries available 24/7 and completed documents returned to the file automatically ———————————————————————————————————————————————————————————— One Jury Verdict. Five More Lawsuits. Great Wolf Lodge Manteca Faces New Bed Bug Claims 2026-10-22 · PR Newswire · Travel, Legal https://www.prnewswire.com/news-releases/one-jury-verdict-five-more-lawsuits-great-wolf-lodge-manteca-faces-new-bed-bug-claims-302916223.html MyBedBugLawyer, led by nationally recognized bed bug trial lawyer Brian Virag, announces three new lawsuits involving the family water park resort. LOS ANGELES, Oct. 22, 2026 -- MyBedBugLawyer (mybedbuglawyer.com) has filed three new lawsuits alleging bed bug exposures at... ———————————————————————————————————————————————————————————— Faruqi & Faruqi, LLP Urges Flotek Industries, Inc. (NYSE: FTK) Investors to Seek Counsel Before the October 26, 2026 Lead Plaintiff Deadline in the Securities Class Action 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/faruqi--faruqi-llp-urges-flotek-industries-inc-nyse-ftk-investors-to-seek-counsel-before-the-october-26-2026-lead-plaintiff-deadline-in-the-securities-class-action-302916340.html Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Flotek Industries to Contact Him Directly to Discuss Their Options NEW YORK, Oct. 22, 2026 -- Faruqi & Faruqi, LLP, a leading national securities law firm,... ———————————————————————————————————————————————————————————— Fitzroy Minerals and Fleet Space Technologies Use Machine Learning to Define New Untested Targets at the Buen Retiro Copper Project, Chile 2026-10-22 · NewMediaWire · AI, Real estate, Energy, Education, Sustainability, Legal, Mining & metals https://www.newmediawire.com/news/fitzroy-minerals-and-fleet-space-technologies-use-machine-learning-to-define-new-untested-targets-at-the-buen-retiro-copper-project-chile-7090793 VANCOUVER, BRITISH COLUMBIA - October 22, 2026 - Fitzroy Minerals Inc. (TSXV: FTZ, OTCQX: FTZFF, FSE: C3Y) (“Fitzroy” or the “Company”) is pleased to announce the results of an integrated seismic and machine-learning (“ML”) targeting study, completed with Fleet Space Technologies (“Fleet”), at the Buen Retiro Copper Project, Copiapo, Chile (“Buen Retiro” or the “Project”). ML targeting generated a ranked set of priority domains (Figure 1) by combining 3D Ambient Noise Tomography (“ANT”) data with prior geophysical surveys, geological models, and approximately 24,400 copper assays from 140 drill holes. The model identified nine areas where the sub-surface characteristics closely resemble the signature of the rocks hosting Buen Retiro’s known copper mineralization. Fleet’s regional and infill ANT surveys mapped the Project’s deeper geology well beyond the depths of current drilling. The technique uses natural seismic noise to build a 3D picture of the rock beneath the surface. This gives Fitzroy a 3D framework to trace known mineralized trends and identify new, previously untested opportunities down to a depth of approximately 400 metres, including toward the 100%-owned Sierra Fritis properties to the east. Extensive alluvial gravel cover in the area makes surface geological mapping and therefore target-generation, much more difficult. Fitzroy has started a 5,000-metre drilling program using diamond and reverse circulation (“RC”) drill rigs. As drill logs and assay results come in, Fitzroy and Fleet will use the new data to update the ML model. In this way, each new drill hole serves three purposes: testing a specific target, improving or validating the ML model, and helping to inform the next drilling decision. Highlights: A ranked portfolio of nine target areas, all completely new and untested, and within 400 m of surface. The targets combine Fleet’s 3D ANT subsurface model with Fitzroy’s own geophysical surveys (IP chargeability, IP resistivity and magnetic susceptibility) and approximately 24,400 copper assays from 140 drill holes. The targets focus on gravel-covered geology and exclude previously mined ground or areas within 200 metres of an existing drill hole. Merlin Marr-Johnson, President and CEO of Fitzroy, commented: “We believe Buen Retiro shares many of the geological characteristics of the major iron oxide copper-gold (IOCG) deposits at Candelaria and Mantoverde, yet the sulphide potential of the wider property has barely been tested. To date, the oxide copper mineralisation and its potential to support a low-capital-intensity, near-term production operation have been the focus. "Now, however, we have a tool with which to test the exploration optionality of this large IOCG system in one of Chile’s most prolific copper-producing regions. By combining advanced 3D subsurface imaging with machine learning and our extensive drilling database, we can now identify and prioritise blind exploration targets beneath the gravel cover. If the ML targeting is successful it will be a cost-effective discovery tool, creating value for shareholders.” Input Data The model combined four 3D geophysical datasets with geology, and copper assay results from drilling (Table 1). Click Here to see Table 1 - Summary of the 4 datasets and copper assay results used in the new ML targeting. From 3D Subsurface Imaging to Ranked Drill Targets Fleet’s work at Buen Retiro began with a regional ANT survey commissioned by Fitzroy in early 2026. The ANT survey was designed to build a better picture of the Project’s deeper geology. This identified structures and zones associated with alteration and brecciation at depth, and gave Fitzroy a 3D framework for further exploration. A higher-resolution, closer-spaced ANT survey was then completed over the main area of interest. This infill survey improved the understanding of the faults and fractures that are interpreted to be the main control on both permeability corridors and associated mineralization. The infill survey also allowed closer correlation of the ANT data with existing geophysical and drilling data. The ML targeting phase then converted this geological and geophysical picture into a set of exploration opportunities. The targets are designed to complement, not replace Fitzroy’s own geological interpretation and drill planning. Targeting Method The targeting method follows four steps, from copper prediction through to ranked, conceptual targets: Prediction. The ML model learned the relationship between geophysical data and copper assays from existing drill holes in order to estimate a quantified uncertainty for any point in space within the survey area. The aim was to predict zones where copper mineralization with grades above a 0.5% Cu threshold within 25-metre blocks of rock across the study area might be located, together with an uncertainty value for each block. The 0.5% Cu threshold is used to visually identify blocks at, or above, the target grade and does not represent a uniform estimate of copper grade per block. Refinement. Blocks were removed from consideration if they fell within the mined-out open pit, mapped gravel cover, or within 200 metres of an existing drill hole, so that target selection would focus on ground with genuine exploration value. Domains. The remaining blocks were grouped into nine geographic areas (“domains”), each representing a cluster of blocks with a similar predicted response (see Figure 1) within high-confidence range and interpreted to be geologically significant. Drill Planning Fitzroy and Fleet are now reviewing drill orientations and sequencing for the list of exploration targets. All of the targets are within the top 400 metres of the surface and Fitzroy has allocated 5,000 metres of combined RC and diamond drilling to test the new areas. As drill logs and assay results come in, Fitzroy and Fleet will compare them against the original target list andupdate the model accordingly. The new results will then feed into future versions of the model, sharpening its predictions and helping guide the next round of drill planning. In this way, each new hole serves two purposes: testing a specific target, updating or validating the ML model, and helping to inform the next drilling decision. Technical Context The new exploration domains are conceptual exploration targets that have not yet been tested by drilling. They mark areas where the combined geophysical and assay data look similar to Buen Retiro’s known zones of copper mineralization. The targets do not confirm the presence, grade, size or continuity of mineralization. The reliability of the model depends on the quality and coverage of the underlying data, and tends to decrease with distance from existing drill holes and with depth. For this reason, the targets are intended to be used alongside conventional geological interpretation and other exploration information, not in place of it. Qualified Person (“QP”) Dr. Scott Jobin-Bevans (P.Geo., Ph.D., PMP), a QP as defined by NI 43-101 and independent geological consultant to the Company, has reviewed and approved the technical information provided in this news release and verified the data disclosed, including the sampling, analytical and test data underlying the technical information contained in this news release. About Fleet Space Technologies Fleet Space Technologies is an Australian frontier technology company that uses seismic-led, 3D subsurface imaging to help geoscience teams understand what lies beneath the surface. Fleet combines its imaging techniques with a client’s existing geology, geophysics and drilling data, using machine learning to turn that combined picture into ranked recommendations for discovery, expansion and development decisions. As new drilling and other data become available, Fleet’s models can be updated, so new results continue to sharpen future subsurface decisions and deliver drilling predictions that stand up against ground truth. About Fitzroy Minerals Fitzroy Minerals is focused on exploring and developing copper assets with substantial upside potential in Chile. The Company’s two lead properties are the Buen Retiro Copper Project located near Copiapo, Chile, and the Caballos Copper Project, located in Valparaiso, Chile. Fitzroy Minerals’ shares are listed on the TSX Venture Exchange under the symbol FTZ and on the OTCQX under the symbol FTZFF. On behalf of the board of Fitzroy Minerals Inc. Merlin Marr-Johnson President and CEO For further information, please contact: Merlin Marr-Johnson +447803712280 mmj@fitzroyminerals.com  For more information on Fitzroy Minerals, please visit the Company's website: www.fitzroyminerals.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. Such forward-looking statements and forward-looking information specifically include, but are not limited to, statements that relate to the success of ML targeting phases, accuracy of ML targeting-based identification and prioritization of exploration targets, the potential mineralization on the Company’s mineral properties, future exploration plans on the Company’s mineral properties, and the timing and results of future exploration. Statements contained in this release that are not historical facts are forward-looking statements that involve various risks and uncertainty affecting the business of the Company. Such statements can generally, but not always, be identified by words such as "expects", "plans", "anticipates", "intends", "estimates", "forecasts", "schedules", "prepares", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. All statements that describe the Company's plans relating to operations and potential strategic opportunities are forward-looking statements under applicable securities laws. These statements address future events and conditions and are reliant on assumptions made by the Company's management, and so involve inherent risks and uncertainties, as disclosed in the Company's periodic filings with Canadian securities regulators, including without limitation, the dangers inherent in exploration, development and mining activities; actual exploration or development plans and costs differing materially from the Company’s estimates; risks specifically related to the accuracy and reliability of machine learning-based prediction models, the ability to obtain and maintain any necessary permits, consents or authorizations required for mining activities; environmental regulations or hazards and compliance with complex regulations associated with mining activities; climate change and climate change regulations; fluctuations in exchange rates; the availability of financing; operations in foreign and developing countries and the compliance with foreign laws, remote operations and the availability of adequate infrastructure; fluctuations in price and availability of energy and other inputs necessary for mining operations; shortages or cost increases in necessary equipment, supplies and labour; regulatory, political and country risks, including local instability or acts of terrorism and the effects thereof; the reliance upon contractors, third parties and joint venture partners; challenges to title or surface rights; the dependence on key personnel and the ability to attract and retain skilled personnel; the risk of an uninsurable or uninsured loss; adverse climate and weather conditions; litigation risk; and competition with other mining companies. As a result of these risks and uncertainties, and the assumptions underlying the forward-looking information, actual results could materially differ from those currently projected, and there is no representation by the Company that the actual results realized in the future will be the same in whole or in part as those presented herein. The Company disclaims any intent or obligation to update forward-looking statements or information except as required by law. Readers are referred to the additional information regarding the Company's business contained in the Company's reports filed with the securities regulatory authorities in Canada. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that could cause actions, events or results not to be as anticipated, estimated or intended. For more information on the Company and the risks and challenges of its business, investors should review the Company's filings that are available at www.sedarplus.ca. ———————————————————————————————————————————————————————————— Karen Ross Joins Women in Power TV 2026-10-22 · EIN Presswire · Legal https://www.einpresswire.com/article/951470500/karen-ross-joins-women-in-power-tv FL, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Karen Ross, attorney and entrepreneur, is set to appear on Women in Power TV, where she shares how perseverance, personal accountability, and client-centered leadership can help navigate adversity and achieve meaningful results. Women in Power is a cinematic docu-series that celebrates visionary women who are rewriting the rules of success. Hosted by Rudy Ma ———————————————————————————————————————————————————————————— Schoenberg Family Law Group Expands to Beverly Hills, Enhancing Statewide Legal Services 2026-10-22 · Newsworthy.ai · Finance, AI, SaaS, Real estate, Legal, Jobs & workplace, Marketing & advertising, Entertainment https://newsworthy.ai/news/202610223083/schoenberg-family-law-group-expands-to-beverly-hills-enhancing-statewide-legal-services Beverly Hills, CA Thursday Oct 22, 2026 @ 5:00 AM Central — Schoenberg Family Law Group, P.C. (SFLG), a California family law firm founded by Certified Family Law Specialist Debra R. Schoenberg, has opened a new office at 9665 Wilshire Blvd, M10, in Beverly Hills. The office marks the firm’s first permanent location in Southern California and gives Los Angeles County clients direct, local access to a firm that has handled complex divorce and custody cases for nearly 40 years. The Beverly Hills office will serve clients throughout Beverly Hills, Bel Air, Holmby Hills, West Hollywood, and the greater Los Angeles area. Attorneys at the new location handle the full range of family law matters, including contested and uncontested divorce, legal separation, child custody and visitation, child and spousal support, prenuptial and postnuptial agreements, and post-judgment modifications. “The opening of our Beverly Hills office marks an exciting new chapter for our firm and expands our ability to serve families across California,” said Debra Schoenberg, Founder and Principal of Schoenberg Family Law Group. “For nearly four decades, we’ve guided clients through some of life’s most difficult transitions with compassion, thoughtful counsel and a strategic approach. We’re proud to extend that same personalized service to individuals and families in Southern California and throughout the state.” A Focus on High-Asset and Complex Family Law Cases High-asset divorces are common in Beverly Hills and the surrounding communities, and they often involve business interests, real estate portfolios, investment accounts, executive compensation, and entertainment-industry income such as residuals and royalties. SFLG’s attorneys work with forensic accountants and valuation experts to identify, value, and divide community and separate property under California law, and to uncover assets when a spouse fails to make full financial disclosure. The firm often resolves cases through negotiation and mediation, maintaining privacy in sensitive family and financial matters. If settlements fail, SFLG's trial attorneys litigate in the Los Angeles County Superior Court, including the Stanley Mosk Courthouse. SFLG aims for negotiated resolutions but prepares each case for trial to ensure clients negotiate from a position of strength. Led by a Board-Certified Family Law Specialist Debra R. Schoenberg is a Certified Family Law Specialist designated by the State Bar of California Board of Legal Specialization, a Board-Certified Family Law Trial Specialist through the National Board of Trial Advocacy, and a Fellow of the American Academy of Matrimonial Lawyers. The Daily Journal has named her one of California’s Top Family Lawyers each year from 2022 through 2026. SFLG was voted the No. 1 Family Law Firm in California for six consecutive years, 2021 through 2026, in a statewide poll of judges, attorneys, and law firm administrators conducted by The Recorder. The San Francisco Business Times has also named the firm one of the Best Places to Work in the Bay Area. Together, the firm’s attorneys bring more than 400 years of collective family law experience. About Schoenberg Family Law Group, P.C. Schoenberg Family Law Group, P.C. is a California family law firm representing clients in divorce, child custody, support, property division, prenuptial and postnuptial agreements, and post-judgment matters. Founded by Debra R. Schoenberg, the firm has practiced family law for nearly 40 years and maintains offices in San Francisco, Beverly Hills, San Mateo, San Jose, and Roseville. People in the Los Angeles area who need guidance on divorce, custody, or another family law matter can schedule a confidential consultation with the firm’s Beverly Hills family law attorneys. Contact Us: Schoenberg Family Law Group, P.C. Beverly Hills 9665 Wilshire Blvd, M10 Beverly Hills, CA 90212 Phone: 310-340-1846 Web: https://www.sflg.com/beverly-hills-family-law/ ———————————————————————————————————————————————————————————— Warner & Fitzmartin Adds Senior Litigation Attorney Bruce Kleinberg 2026-10-22 · 24-7 Press Release · Healthcare, Legal https://www.24-7pressrelease.com/press-release/539815/warner-fitzmartin-adds-senior-litigation-attorney-bruce-kleinberg Board Certified Trial Lawyer Brings a Medical Degree to Injury Cases ———————————————————————————————————————————————————————————— Grayhawk Safety Provides OSHA Expert Witness and Workplace Accident Investigation Services for Serious Incidents and Litigation 2026-10-22 · MarketersMEDIA · Healthcare, Legal, Jobs & workplace https://news.marketersmedia.com/grayhawk-safety-provides-osha-expert-witness-and-workplace-accident-investigation-services-for-serious-incidents-and-litigation/89206910 Grayhawk Safety & Health Consulting provides OSHA expert witness and workplace accident investigation services for serious incidents and litigation. Led by Randy Gray, with 25 years of OSHA experience, the company offers impartial investigations, technical analysis, and litigation support for both plaintiff and defense counsel. -- When a serious workplace accident occurs, determining what happened, why it happened an ———————————————————————————————————————————————————————————— [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 2026-10-22 · Roche · Finance, AI, SaaS, Healthcare, Real estate, Automotive, Food & drink, Industrial, Biotech & pharma, Sustainability, Investing & markets, Legal, Government & policy, Jobs & workplace, Marketing & advertising, Software & IT, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-22 Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 Group sales were +6% at constant exchange rates (CER)1, +1% when reported in CHF and +7% in USD2, in the first nine months of 2026, driven by high demand for our innovative medicines and diagnostics. In the third quarter, sales grew +7% (CER) and +8% in CHF (+7% in USD), as exchange rates stabilised. Pharmaceuticals Division sales were +7% at CER, +2% when reported in CHF and +8% in USD, in the first nine months, due to continued high demand for medicines to treat severe diseases; Xolair (chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers. Diagnostics Division sales were +4% at CER, stable when reported in CHF and +6% in USD, in the first nine months, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Highlights: US approval for Tecentriq for the adjuvant treatment of stage-III DNA mismatch repair colon cancer, Gazyva/Gazyvaro for reducing the risk of relapse in patients 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome and Enspryng in thyroid eye disease US Priority Reviews for fenebrutinib in both relapsing and primary progressive multiple sclerosis and Enspryng in MOGAD, an autoimmune disease; vamikibart filing acceptance in uveitic macular edema, a leading cause of vision loss EU approval for Susvimo in neovascular age-related macular degeneration (nAMD), a severe eye disease, and Ocrevus in paediatric relapsing multiple sclerosis; EMA validation of application for Enspryng in MOGAD in Europe Positive data for: sefaxersen in an autoimmune condition affecting kidney function (phase III), Lunsumio in blood cancer (phase III), Tam-Peli in relapsed small-cell lung cancer (phase III) as well as enicepatide and petrelintide in overweight or obesity and type 2 diabetes (both phase II) US clearance for Elecsys pTau217 test, providing clinicians across primary and specialty care with a single-biomarker blood test to aid in identifying amyloid pathology associated with Alzheimer’s disease Launch of two new, real-time PCR tests to support public health epidemic response to the US outbreak of the Cyclospora cayetanensis parasite Delivery of molecular tests to support the Democratic Republic of the Congo health ministry-led response to the Ebola outbreak Manufacturing and R&D capacity expansion: Hillsboro injectable medicines facility and Innovation Center Boston for cardiovascular, renal and metabolic diseases in the US and small molecules facility in Basel, Switzerland Outlook for 2026 confirmed Roche CEO Thomas Schinecker: “In the third quarter, we delivered strong sales growth of +7% at constant exchange rates and +8% in Swiss francs. Most importantly, we continued to make meaningful progress for patients. We advanced another five potential new medicines into the final stage of development this year and now aim to bring up to 20 new medicines to patients by 2030. The US FDA granted Priority Review for fenebrutinib in both relapsing and primary progressive multiple sclerosis, bringing us closer to delivering the first high-efficacy, brain-penetrant oral therapy to patients. Giredestrant is also under FDA Priority Review in both early-stage and advanced breast cancer, and we are fully prepared to launch later this year, pending approval. In Diagnostics, we received US FDA clearance for Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test for Alzheimer’s disease that supports both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings.  We confirm our full-year outlook.” Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs. SalesCHF millionsAs % of sales% change January–September 2026202520262025At CERIn CHFIn USD Group 46,49345,862100.0100.0+6+1+7          Pharmaceuticals Division36,21235,55577.977.5+7+2+8 United States18,71218,79840.241.0+50  Europe6,8196,81814.714.9+20  Japan2,3522,1395.14.7+25+10  International8,3297,80017.916.9+10+7           Diagnostics Division10,28110,30722.122.5+40+6 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Group sales In the first nine months of 2026, Roche sales were +6% at CER, +1% when reported in CHF, to CHF 46.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. This currency impact reversed in the third quarter. Sales growth in the Pharmaceuticals Division was +7% at CER, +2% when reported in CHF, to CHF 36.2 billion, with medicines for severe diseases continuing their strong growth. The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 16.8 billion, an increase of +12% at CER, or +6% in CHF, compared to the first nine months of 2025. Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) decreased by a combined CHF 0.4 billion at CER, or CHF 0.6 billion in CHF. In the United States, sales were +5% at CER, stable when reported in CHF, due to continued growth of Xolair, Hemlibra, Ocrevus, Polivy (blood cancer) and Tecentriq (cancer immunotherapy). This growth more than compensated for the lower sales of Kadcyla (breast cancer) and Perjeta (breast cancer). Sales in Europe were +2% at CER, stable when reported in CHF, as the growing demand for Ocrevus, Phesgo and Evrysdi (spinal muscular atrophy) more than offset the impact of biosimilar competition on Actemra/RoActemra and the conversion to Phesgo on Perjeta. In Japan, sales were +25% at CER, +10% when reported in CHF, mainly due to product supply to third parties and continued growth of Lunsumio (blood cancer), Hemlibra, Polivy, Elevidys (Duchenne muscular dystrophy) and Vabysmo. There was also a positive impact of timing effects related to the implementation of a new enterprise resource planning (ERP) system. Sales in the International region were +10% at CER, +7% when reported in CHF, led by higher sales of Phesgo, Vabysmo, Hemlibra, Ocrevus and Evrysdi. In China, sales were stable at CER and when reported in CHF, driven by continued growth of Phesgo, Vabysmo, Alecensa and Polivy. The increase was partially offset by lower sales of Perjeta due to the conversion to Phesgo and Xofluza due to a milder flu season in 2025. The Diagnostics Division’s sales were +4% at CER, stable when reported in CHF, to CHF 10.3 billion as growth in demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, unchanged when reported in CHF, driven by higher sales of clinical chemistry and immunodiagnostic products. In North America, sales were +9% at CER, +3% when reported in CHF, with growth across the Core Lab, Pathology Lab and Molecular Lab customer areas. Sales in Asia-Pacific were -4% at CER, or -8% when reported in CHF, due to the healthcare pricing reforms in China. In Latin America, sales growth was +12% at CER, or +11% when reported in CHF. Pharmaceuticals: key developments CompoundMilestone Regulatory Enspryng Thyroid eye diseaseFDA approves Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) FDA approval based on phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, regardless of TED activity or duration. Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home subcutaneous treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered. Enspryng is an anti-IL-6R monoclonal antibody using novel recycling antibody technology designed to inhibit IL-6 signalling upstream of autoantibody-driven pathology. TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the US that can lead to facial disfigurement and vision-threatening complications if left untreated. More information: Media Release, 16 October 2026 Tecentriq Different types of cancerFDA approves Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer The approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. It is the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care. Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years. Approval marks the twelfth indication for Tecentriq in the US. More information: Media Release, 9 October 2026 Fenebrutinib Multiple sclerosisFenebrutinib is the first BTK inhibitor to receive US FDA filing acceptance in both relapsing and primary progressive multiple sclerosis Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in phase III RMS trials (FENhance 1 and 2) while showing a consistent, positive trend in delaying disability. Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus. Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression. If approved, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million people living with MS in the US. More information: Media Release, 30 September 2026 Susvimo Severe eye diseasesEuropean Commission approves Susvimo for the treatment of neovascular age-related macular degeneration   By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD. Susvimo helps people with nAMD maintain their vision with as few as two treatments per year. Data from the phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections. nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European Union. More information: Media Release, 21 September 2026 Enspryng MOGADFDA grants Priority Review for Enspryng for MOGAD, an autoimmune disease with no approved treatments If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease). The filing acceptance is based on the phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%. The European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe, with a decision expected in Q3 2027. More information: Media Release, 10 September 2026 Phase III, pivotal and other key read-outs Sefaxersen IgA nephropathyPositive interim data shows sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential. Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage. Interim data will be presented at an upcoming medical meeting and shared with health authorities. More information: Media Release, 23 September 2026 Enicepatide ObesityRoche announces positive phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycaemic control. By week 48, 90% of patients in the 24 mg enicepatide arm met the type-2-diabetes glycaemic target of ≤6.5% HbA1c, while 62% achieved normoglycaemia (HbA1c <5.7%). At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau. More information: Media Release, 22 September 2026 Lunsumio Blood cancerRegimen based on Lunsumio significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment. Data reinforce the potential of this regimen based on Lunsumio to improve clinical outcomes, while offering a tolerable safety profile, a simple dosing schedule and outpatient administration. CELESTIMO is the confirmatory study required to convert the accelerated approval / conditional marketing authorisation of Lunsumio monotherapy for third-line or later (3L+) follicular lymphoma to full approval, as well as to secure an indication in second-line or later (2L+) follicular lymphoma. Data will be submitted to health authorities and presented at an upcoming medical meeting. More information: Media Release, 17 September 2026 Tam-Peli Lung cancerRoche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%. The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN platform, designed to maximise antitumour activity while minimising off-target toxicity. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau across multiple tumour types, with plans to rapidly initiate global trials. Tam-Peli has received US FDA and China CDE Breakthrough Therapy Designations for relapsed small-cell lung cancer. More information: Media Release, 13 September 2026 Vabysmo Severe eye diseasesVabysmo demonstrates sustained two-year results in a difficult-to-treat form of nAMD The SALWEEN study showed significant improvements in vision and retinal health. More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions. By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden. More information: Media Release, 28 August 2026 Other ESMO presentation Lung and breast cancer portfolio Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard-of-care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer. Patient-reported outcomes from phase III lidERA study showed that improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer. Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3-targeted ADC, to deliver robust efficacy with a favourable safety profile in high-unmet-need solid tumours.   More information: Media Release, 19 October 2026 Vamikibart Uveitic macular edemaRoche presents new phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks. UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated. The FDA has accepted Roche’s Biologics License Application (BLA), with an approval decision expected by July 2027. More information: Media Release, 10 October 2026 Vabysmo Severe eye diseasesRoche presents new data at EURETINA, highlighting the real-world effectiveness and safety of Vabysmo across major retinal conditions New real-world results for Vabysmo in nAMD, diabetic macular edema and retinal vein occlusion reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals. Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care. With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide.   More information: Media Release, 1 October 2026 Giredestrant Breast cancerGiredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus. By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes. The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026. More information: Media Release, 1 October 2026 Board of Directors nominationRoche proposes Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to its Board of Directors at the 2027 Annual General Meeting Roche’s Board of Directors has approved to propose Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board at the Annual General Meeting on 9 March 2027. Roche Chairman Severin Schwan highlighted Dr Weber’s extensive healthcare industry knowledge and leadership experience as valuable assets for the Board. Roche continues its commitment to transformative medicines and diagnostics, focusing on major disease areas and global healthcare challenges. More information: Media Release, 23 September 2026 Innovation Center BostonRoche announces grand opening of its Innovation Center Boston to drive advancements in cardiovascular, renal and metabolic diseases The centre will be a hub for Roche and Genentech, bringing together expertise in cardiovascular, renal and metabolic diseases, as well as for data science and AI specialists to drive innovation in drug discovery and development. It will expand Roche’s and Genentech’s presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubs. This is part of Roche and Genentech’s USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon. More information: Media Release, 17 September 2026 Hillsboro facilityGenentech, Roche’s US subsidiary, announces a USD 750 million manufacturing expansion in Hillsboro, Oregon The new facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end US drug manufacturing capabilities. Approximately USD 750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs. Flexible manufacturing capacity will support advanced drug delivery devices that can provide patients with more convenient ways to receive treatment. More information: Media Release, 20 August 2026 Pharmaceuticals sales SalesCHF millionsAs % of sales% change January–September2026202520262025At CERIn CHF Pharmaceuticals Division36,21235,555100.0100.0+7+2 United States18,71218,79851.752.9+50 Europe6,8196,81818.819.2+20 Japan2,3522,1396.56.0+25+10 International8,3297,80023.021.9+10+7 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Top 20 best-selling pharmaceuticals (% change at CER1)TotalUnited StatesEuropeJapanInternational CHF m%CHF m%CHF m%CHF m%CHF m% Ocrevus Multiple sclerosis5,317+73,581+51,136+9--600+21 Hemlibra Haemophilia A3,750+122,006+9769+5291+20684+23 Vabysmo Eye diseases (nAMD, DME, RVO)3,196+102,060+2585+7131+41420+65 Tecentriq Cancer immunotherapy2,615+51,243+8626-2245+6501+9 Xolair3 Chronic hives, food allergies2,521+202,521+20------ Phesgo Breast cancer2,064+18486-1657+11152+24769+43 Perjeta3 Breast cancer2,040-8824-10361-1338-20817-3 Actemra/RoActemra3 RA, COVID-191,621-10795-9328-26232+14266-4 Evrysdi Spinal muscular atrophy1,470+18497+12504+1465+7404+33 Kadcyla3 Breast cancer1,339-9442-19370-565+9462-2 Polivy Blood cancer1,302+24606+29204-9176+30316+44 Alecensa Lung cancer1,213+6391-1189-3154+15479+15 MabThera/Rituxan3 Blood cancer, RA919+3605+1294-88-16212-10 Activase/TNKase3 Cardiac diseases830+6792+5----38+12 Gazyva/Gazyvaro3 Blood cancer, lupus nephritis751+7369+4176-228+28178+25 Herceptin3 Breast and gastric cancer695-12140-15205-63-35347-13 Avastin3 Various cancer types639-12195-856+556-43332-9 Columvi Blood cancer327+67146+2492+113--89+167 Enspryng Acute inflammation of brain, spinal cord and optic nerves319+2879+1834+18138+3068+42 Pulmozyme3 Cystic fibrosis303-12214-1143-111+3845-18 DME: diabetic macular edema / nAMD: neovascular or ‘wet’ age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis Diagnostics key developments ProductMilestone Elecsys pTau217 Alzheimer’s diseaseRoche receives FDA clearance for Elecsys pTau217, advancing Alzheimer’s disease assessment across primary and specialty care It is the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings. The test delivers consistency across clinical settings by using the same validated cut-offs in primary and specialty care. It is designed for broad implementation across Roche’s installed base of more than 4,500 cobas laboratory instruments in the US supporting access through existing laboratory infrastructure.   More information: Investor Update, 24 August 2026 Diagnostics sales SalesCHF millionsAs % of sales% change January–September2026202520262025At CERIn CHF Diagnostics Division10,28110,307100.0100.0+40 Customer areas       Core Lab5,7555,68856.055.2+5+1 Molecular Lab1,8361,86117.918.1+3-1 Near Patient Care1,3481,47713.114.3-5-9 Pathology Lab1,3421,28113.012.4+10+5 Regions       Europe, Middle East, Africa3,6983,68636.035.8+30 North America3,3893,30532.932.1+9+3 Asia-Pacific2,3432,54722.824.7-4-8 Latin America8517698.37.4+12+11 More information on Roche’s performance in the first nine months of 2026: 9M 2026 presentation Appendix with tables  About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceuticals Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] CER (Constant Exchange Rates). The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2026 and 2025 results at constant exchange rates (the average rates for the year ended 31 December 2025). For the definition of CER, see page 178 of the Roche Finance Report 2025. [2] USD (US dollars). The percentage changes for selected sales figures at US dollars are calculated by translating both the 2026 and 2025 sales figures at the respective average US dollar exchange rate for the period in question. This supplementary information is provided to assist readers when assessing comparability with other companies. [3] Products launched before 2015. Cautionary statement regarding forward-looking statements This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 687 5 284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 688 80 27 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 688 48 14 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com   Attachments Communications appendix tables_YTD Sep 2026_Sales_02102026 Media Investor Release Roche Q3 2026 English ———————————————————————————————————————————————————————————— AMANDA HARRINGTON NAMED AUSTRALASIAN LAWYER AND NZ LAWYER ELITE WOMAN 2026 2026-10-22 · EIN Presswire · Legal https://www.einpresswire.com/article/951379446/amanda-harrington-named-australasian-lawyer-and-nz-lawyer-elite-woman-2026 Amanda Harrington, Pivotal Law Group Amanda Harrington of Pivotal Law Group, has been named among Australia and New Zealand’s Elite Women 2026 for her achievements and innovative legal practice. MELBOURNE, AUSTRALIA, October 22, 2026 / EINPresswire.com / -- Amanda Harrington , principal and founder of Pivotal Law Group Pty Ltd , has been named as one of the top female lawyers in Australia and New Zealand, selected fo ———————————————————————————————————————————————————————————— Five Trusted High-Net-Worth Divorce Law Firms in China 2026: Safeguarding Complex Family Asset Portfolios 2026-10-22 · EIN Presswire · Real estate, Legal https://www.einpresswire.com/article/951403140/five-trusted-high-net-worth-divorce-law-firms-in-china-2026-safeguarding-complex-family-asset-portfolios BEIJING YUANJIA LAW FIRM Navigating Cross-Border Litigation, Wealth Division, and Complex Marital Property Disputes CALIFORNIA, CA, UNITED STATES, October 21, 2026 / EINPresswire.com / -- BEIJING, October 2026 — Five China-based law firms have been identified in a 2026 market-mapping review of counsel for high-net-worth divorce, a segment in which marital estates increasingly include operating companies, domestic and ———————————————————————————————————————————————————————————— Computer Task Group Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Exposure of Social Security Numbers and Health Data 2026-10-22 · PR Newswire · Healthcare, Cybersecurity, Legal https://www.prnewswire.com/news-releases/computer-task-group-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-exposure-of-social-security-numbers-and-health-data-302916253.html National class action law firm offers free, confidential case evaluations to Computer Task Group employees, contractors, clients, and others whose information may have been exposed. NEWTOWN, Pa., Oct. 21, 2026 -- Edelson Lechtzin LLP, a national class action law firm, is... ———————————————————————————————————————————————————————————— STS Aviation Group Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Exposure of Social Security Numbers, Financial, and Medical Data 2026-10-22 · PR Newswire · Healthcare, Aerospace & defense, Cybersecurity, Legal https://www.prnewswire.com/news-releases/sts-aviation-group-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-exposure-of-social-security-numbers-financial-and-medical-data-302916251.html National class action law firm offers free, confidential case evaluations to STS Aviation Group customers, employees, and others whose personal information may have been exposed in the data breach. NEWTOWN, Pa., Oct. 21, 2026 -- Edelson Lechtzin LLP, a national class action... ———————————————————————————————————————————————————————————— The Money Store Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Ransomware Group Claims Theft of Mortgage Data 2026-10-22 · PR Newswire · Real estate, Cybersecurity, Banking, Legal https://www.prnewswire.com/news-releases/the-money-store-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-ransomware-group-claims-theft-of-mortgage-data-302916246.html National class action law firm offers free, confidential case evaluations to The Money Store customers and others whose information may have been exposed. NEWTOWN, Pa., Oct. 21, 2026 -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy... ———————————————————————————————————————————————————————————— Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit 2026-10-22 · PR Newswire · Finance, Biotech & pharma, Legal https://www.prnewswire.com/news-releases/robbins-llp-reminds-uncy-investors-of-the-pending-lead-plaintiff-deadline-in-the-unicycive-therapeutics-inc-securities-class-action-lawsuit-302916105.html SAN DIEGO, Oct. 21, 2026 -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June... ———————————————————————————————————————————————————————————— Compass, Inc. (COMP) Class Action Lawsuit Seeks Recovery for Investors; December 8, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP 2026-10-22 · PR Newswire · Finance, Real estate, Legal https://www.prnewswire.com/news-releases/compass-inc-comp-class-action-lawsuit-seeks-recovery-for-investors-december-8-2026-deadline--contact-kessler-topaz-meltzer--check-llp-302916043.html Are you a former Anywhere Real Estate Inc. shareholder who exchanged your shares of Anywhere stock for Compass, Inc. common stock in connection with the January 2026 merger? Affected COMP Investor Summary Who: Compass, Inc. (NYSE: COMP) What: Securities fraud class action lawsuit filed... ———————————————————————————————————————————————————————————— Webull Corporation Class Action Lawsuit Seeks Recovery for Investors; December 7, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/webull-corporation-class-action-lawsuit-seeks-recovery-for-investors-december-7-2026-deadline--contact-kessler-topaz-meltzer--check-llp-302916039.html Did you buy BULL securities between April 26, 2025 and October 6, 2026? Affected BULL Investor Summary Who: Webull Corporation (NASDAQ: BULL) What: Securities fraud class action lawsuit filed Class Period: April 26, 2026 through October 6, 2026 Deadline to Seek Lead Plaintiff Status:... ———————————————————————————————————————————————————————————— Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Ecology Auto Parts, Inc., for Alleged Failure to Provide Required Meal Periods and Rest Periods 2026-10-22 · PR Newswire · Logistics, Legal, Marketing & advertising https://www.prnewswire.com/news-releases/employment-law-attorneys-at-blumenthal-nordrehaug-bhowmik-de-blouw-llp-filed-a-lawsuit-against-ecology-auto-parts-inc-for-alleged-failure-to-provide-required-meal-periods-and-rest-periods-302916124.html Ecology Auto Parts, Inc., a provider of auto-wrecking and logistics services, allegedly failed to provide employees with accurate wages due to missed meals and break breaks. This allegedly resulted in violations of various California Labor Codes. **THIS IS AN ATTORNEY ADVERTISEMENT** SAN... ———————————————————————————————————————————————————————————— CELH Deadline: CELH Investors Have Opportunity to Lead Celsius Holdings, Inc. Securities Fraud Lawsuit 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/celh-deadline-celh-investors-have-opportunity-to-lead-celsius-holdings-inc-securities-fraud-lawsuit-302916016.html NEW YORK, Oct. 21, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Celsius Holdings, Inc. (NASDAQ: CELH) between February 21, 2025 and June 3, 2026, both dates inclusive (the "Class Period"), of the important November 3,... ———————————————————————————————————————————————————————————— ROSEN, SKILLED INVESTOR COUNSEL, Encourages AppLovin Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – APP 2026-10-22 · GlobeNewswire · Finance, Legal https://www.globenewswire.com/news-release/2026/10/22/3385995/673/en/rosen-skilled-investor-counsel-encourages-applovin-corporation-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-app.html NEW YORK, Oct. 21, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AppLovin Corporation (NASDAQ: APP) between February 12, 2026 and August 5, 2026, inclusive (the “Class Period”), of the important November 16, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— TTAN ALERT: Investigation Launched into ServiceTitan, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/ttan-alert-investigation-launched-into-servicetitan-inc-rgrd-law-attorneys-encourage-investors-and-potential-witnesses-to-contact-law-firm-302916112.html SAN DIEGO, Oct. 21, 2026 -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving ServiceTitan, Inc. (NASDAQ: TTAN). If you have information that could assist in the ServiceTitan investigation or if you are a... ———————————————————————————————————————————————————————————— Greenberg Traurig's Cesar Alvarez Receives Greater Miami Chamber of Commerce 2026 Sand in My Shoes® Award 2026-10-22 · PR Newswire · Legal https://www.prnewswire.com/news-releases/greenberg-traurigs-cesar-alvarez-receives-greater-miami-chamber-of-commerce-2026-sand-in-my-shoes-award-302916091.html Global Firm's Senior Chairman Honored for Leadership and Service that Strengthens Miami Communities MIAMI, Oct. 21, 2026 -- Cesar L. Alvarez, Senior Chairman of global law firm Greenberg Traurig, P.A., received the Greater Miami Chamber of Commerce 2026 Sand in My Shoes®... ———————————————————————————————————————————————————————————— DAVA Investors Have Opportunity to Lead Endava plc Securities Fraud Lawsuit 2026-10-22 · PR Newswire · Finance, Legal https://www.prnewswire.com/news-releases/dava-investors-have-opportunity-to-lead-endava-plc-securities-fraud-lawsuit-302916010.html NEW YORK, Oct. 21, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Endava plc (NYSE: DAVA) between September 4, 2025 and September 21, 2026, both dates inclusive (the "Class Period"). A... ———————————————————————————————————————————————————————————— Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027 2026-10-22 · ACN Newswire · Finance, Healthcare, Food & drink, Industrial, Biotech & pharma, Legal, Nonprofits, Internet & apps https://www.acnnewswire.com/press-release/english/110981/ Mountain View, CA, 21 Oct, 2026 - Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027. Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/unicycive-therapeutics. "We are pleased that the FDA has accepted the resubmission of our NDA for OLC and assigned a PDUFA date," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "This resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor's facility was last inspected by the FDA in March 2024 and received 'No Action Indicated' status. We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia." The Company does not know whether the FDA will decide to conduct a pre-approval inspection of the new third-party DP vendor. Additionally, if the original third-party manufacturing vendor is inspected in the near term and finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to seek FDA alignment on a shorter approval timeline. The Company resubmitted the NDA following the second CRL, which cited deficiencies previously identified at the original third-party manufacturer of the drug product, which the FDA had not been able to re-inspect during the prior submission review. The timing and outcome of any FDA inspection of the original third-party vendor will be determined solely by the FDA. The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, as well as CMC data. The FDA did not raise any concerns regarding OLC's preclinical or clinical data, including safety data, included in the original NDA submission. About Oxylanthanum Carbonate OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035. About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.[1] Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream. [1] Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com. Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; Unicycive's clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; Unicycive's dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of its NDA; the risk that the inspection of the original or new third-party manufacturing vendor may not occur within a timeframe that benefits its regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm its financial condition and increase its costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of its products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Contacts: Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com Media Contact: Unicycive Therapeutics, media@unicycive.com Additional Contact: David Shapiro, B2i Digital, Inc., +1 212-579-4844, david@b2idigital.com B2i Digital Social Media: LinkedIn X Facebook Instagram YouTube TikTok Stocktwits Reddit Pinterest Threads To learn more about the B2i Digital Media Network, visit:  https://b2idigital.com/media-network SOURCE: Unicycive Therapeutics, Inc. ———————————————————————————————————————————————————————————— St. Charles, MO Stepparent Adoption Attorney For Consent Disputes Announced 2026-10-21 · MarketersMEDIA · Legal https://news.marketersmedia.com/st-charles-mo-stepparent-adoption-attorney-for-consent-disputes-announced/89206923 Lecour Family Law (636-685-0440) has announced its stepparent adoption services for St. Charles County clients facing cases where the other parent’s consent is disputed, unavailable, or legally waived under Missouri law. -- Lecour Family Law has announced the availability of its stepparent adoption services for clients in the St. Charles area. The firm handles cases in which the other legal parent’s consent cannot be ———————————————————————————————————————————————————————————— Uninsured Motorist Coverage in Texas: León Law Firm Explains How Claims Get Paid 2026-10-21 · MarketersMEDIA · Insurance, Legal https://news.marketersmedia.com/uninsured-motorist-coverage-in-texas-leon-law-firm-explains-how-claims-get-paid/89206922 A new León Law Firm guide explains how uninsured and underinsured motorist coverage works in Texas, why minimum liability limits often fall short and what injured drivers must do to get paid. -- The León Law Firm, P.C. has published a guide to uninsured motorist coverage in Texas, explaining how drivers can recover when the person who hit them has no insurance or not enough of it. The guide is available at https://th ———————————————————————————————————————————————————————————— Delta Air Lines announces September quarter 2026 financial results 2026-10-09 · Delta Air Lines · Finance, Healthcare, Energy, Retail, Travel, Aerospace & defense, Cybersecurity, Sustainability, Insurance, Legal, Oil & gas https://news.delta.com/delta-air-lines-announces-september-quarter-2026-financial-results Delta Air Lines (NYSE: DAL) today reported financial results for the September quarter and provided its outlook for the December quarter and full year 2026.  “Demand remains strong, supported by consumers’ growing preference for experiences and travel, with air travel continuing to be one of the best values in the consumer economy," said Ed Bastian, Delta's Chief Executive Officer. "Against this backdrop, we delivered September quarter pre-tax profit of $1.5 billion, matching last year's performance, and generated $1.9 billion of free cash flow year-to-date. Our resilience reflects the structural durability we’ve built over many years, enabling us to effectively navigate one of the most elevated fuel environments in recent times. The foundation of that resilience is our people, whose commitment to delivering for our customers continues to set Delta apart." Bastian continued, "For the full year, we expect to generate a pre-tax profit of roughly $4.5 billion, absorbing a $6 billion increase in fuel costs. Looking ahead, our focus remains on profitable growth and delivering against our long-term financial framework, including mid-teens margins and returns, durable free cash flow and gross leverage of approximately one times." September Quarter 2026 GAAP Financial Results Operating revenue of $20.2 billion Operating income of $1.5 billion with an operating margin of 7.2% Pre-tax income of $1.1 billion with a pre-tax margin of 5.3% Earnings per share of $1.15 Operating cash flow of $1.7 billion September Quarter 2026 Non-GAAP Financial Results  Operating revenue of $17.6 billion Operating income of $1.7 billion with an operating margin of 9.4% Pre-tax income of $1.5 billion with a pre-tax margin of 8.5% Earnings per share of $1.72 Operating cash flow of $1.7 billion Read the full release on PR Newswire via download. Forward Looking Statements Statements made in this press release that are not historical facts, including statements regarding our estimates, expectations, beliefs, intentions, projections, goals, aspirations, commitments or strategies for the future, should be considered “forward-looking statements” under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees or promised outcomes and should not be construed as such. All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the estimates, expectations, beliefs, intentions, projections, goals, aspirations, commitments and strategies reflected in or suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, the possible effects of serious accidents involving our aircraft or aircraft of our airline partners; breaches or lapses in the security of technology systems we use and rely on, which could compromise the data stored within them, as well as failure to comply with evolving global privacy and security regulatory obligations or adequately address increasing customer focus on privacy issues and data security; disruptions in our information technology infrastructure; failure of the technology we use or depend on to perform effectively, including new and emerging technologies; increases in the price of aircraft fuel; extended disruptions in the supply of aircraft fuel, including from Monroe Energy, LLC (“Monroe”), our wholly-owned subsidiary that operates the Trainer refinery; failure to achieve expected results or returns from our commercial relationships with airlines in other parts of the world and the investments we have in certain of those airlines; the effects of a significant disruption in the operations or performance of third parties on which we rely; failure to comply with the financial or other covenants in our financing agreements; labor-related disruptions; the effects on our business of seasonality and other factors beyond our control, such as changes in value in our equity investments, severe weather conditions, natural disasters or other environmental events, including from the impact of climate change; failure or inability of insurance to cover a significant liability at Monroe’s refinery; failure to comply with existing and future environmental regulations to which Monroe’s refinery operations are subject, including those relating to the discharge of materials into the environment, waste management, pollution prevention measures and greenhouse gas emissions; significant damage to our reputation and brand, including from exposure to significant adverse publicity or inability to achieve certain sustainability goals; our ability to retain senior management and other key employees, and to maintain our company culture; disease outbreaks or other public health threats, and measures implemented to combat them; the effects of terrorist attacks, geopolitical conflict or security events; competitive conditions in the airline industry; extended interruptions or disruptions in service at major airports where we operate; significant problems associated with types of aircraft or engines we operate; the effects of extensive regulatory and legal compliance requirements we are subject to; the impact of laws and regulations governing environmental protection, including but not limited to regulation of hazardous substances, increased regulation to reduce emissions and other risks associated with climate change, and the cost of compliance with more stringent environmental regulations; and unfavorable economic or political conditions in the markets in which we operate or volatility in currency exchange rates. Additional information concerning risks and uncertainties that could cause differences between actual results and forward-looking statements is contained in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other filings filed with the SEC from time to time. Caution should be taken not to place undue reliance on our forward-looking statements, which represent our views only as of the date of this press release, and which we undertake no obligation to update except to the extent required by law. ———————————————————————————————————————————————————————————— Bayer operationally on track, decisive progress on strategic priorities 2026-08-04 · Bayer · Finance, AI, SaaS, Healthcare, Retail, Media, Biotech & pharma, Legal, Marketing & advertising, Agriculture https://www.bayer.com/media/en-us/bayer-operationally-on-track-decisive-progress-on-strategic-priorities/ Leverkusen, August 4, 2026 – The Bayer Group continued to make headway in the second quarter of 2026, capping off a successful first half of the year. “Operationally, we’re well on track to achieve our full-year outlook,” CEO Bill Anderson said when presenting the company’s Half-Year Financial Report on Tuesday. All three divisions are on target, he noted. Bayer has also made decisive progress on its long-term strategic priorities, Anderson emphasized. The landmark US Supreme Court ruling in the Durnell case is one such example, he said, adding that it puts Bayer in a stronger position for the proposed class settlement agreement. “Overall, our containment strategy is in a strong place, with some important milestones ahead,” Anderson explained. Bayer is also advancing its other strategic priorities, Anderson said, pointing to progress in rejuvenating the Pharmaceuticals pipeline and executing the Five-Year Framework to improve profitability at Crop Science. In addition, Bayer’s lean, entrepreneurial operating model is driving efficiency gains across the entire Group, while also positioning the company well to effectively capitalize on the opportunities of artificial intelligence, he noted. “Over the past two and a half years, we’ve progressed in each of these areas. Each of them has demanded intense focus – and it’s imperative that we maintain that focus,” Anderson emphasized. “We’re concentrating on delivering our commitments and ensuring the best future for Bayer.” Dr. Judith Hartmann, who took over the CFO role in June, shared her perspective. “I am excited to be part of the team driving Bayer forward at such an important time in its journey. While we’ve delivered strong strategic and financial progress, including meaningful steps on our balance sheet, important opportunities remain ahead of us. Bayer benefits from a powerful innovation engine and growth prospects across all three businesses. Our financial priorities are clear: to further strengthen the balance sheet, enhance productivity and improve cash generation, while continuing to invest behind growth and creating sustainable value,” Hartmann said. Sales and EBITDA before special items up against prior year Group sales came in at 10.872 billion euros in the second quarter of 2026, up 2.2 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). There was a negative currency effect of 63 million euros (Q2 2025: 550 million euros). EBITDA before special items increased by 1.9 percent to 2.144 billion euros, and included a negative currency effect of 70 million euros (Q2 2025: 184 million euros). EBIT amounted to 827 million euros (Q2 2025: 13 million euros) after net special charges of 172 million euros (Q2 2025: 981 million euros) that were primarily attributable to litigation-related expenses. Net income came in at 219 million euros (Q2 2025: minus 199 million euros). Core earnings per share decreased by 16.7 percent to 0.95 euros, with the improvement in earnings in the Crop Science Division only partially offsetting a normalization in tax expense and lower earnings in the Reconciliation. Free cash flow amounted to minus 371 million euros (Q2 2025: 125 million euros), partly due to higher payments to resolve litigation. Net financial debt came in at 33.647 billion euros as of June 30, 2026, representing a 3.5 percent increase against March 31, 2026, and a 1.1 percent rise from a year-on-year perspective. Crop Science: Topline growth and efficiencies in cost of goods sold drive higher earnings In the agricultural business (Crop Science), sales increased by 3.5 percent (Fx & portfolio adj.) to 4.910 billion euros. Business was up at Soybean Seed & Traits and Cotton Seed following the return of the dicamba label in the United States, with gains of 16.9 and 69.2 percent (Fx & portfolio adj.), respectively. By contrast, sales at Corn Seed & Traits were down 2.5 percent (Fx & portfolio adj.), with substantial gains in Europe/Middle East/Africa and Asia/Pacific only partially offsetting lower volumes in North America, where business was impacted by volume phasing into the first quarter. In the Crop Protection business, growth was primarily driven by the division’s glyphosate-based herbicides. Sales of these products rose by 12.6 percent (Fx & portfolio adj.) fueled by higher volumes and prices, especially in Europe/Middle East/Africa. The Insecticides business recorded a 15.9 percent (Fx & portfolio adj.) increase in sales that was mainly attributable to higher volumes and prices in Europe/Middle East/Africa and Asia/Pacific. EBITDA before special items at Crop Science advanced by 30.2 percent to 902 million euros. The increase in earnings was largely fueled by high-margin topline growth as well as a decline in the cost of goods sold that was driven by efficiency programs, as the division continues implementation of its Five-Year Framework. The EBITDA margin before special items increased by 3.9 percentage points to 18.4 percent. Pharmaceuticals: Continued growth momentum for Nubeqa™ and Kerendia™ Sales of prescription medicines (Pharmaceuticals) came in at 4.458 billion euros, in line with the prior year (Fx & portfolio adj. plus 0.8 percent). The division again registered significant gains for its cancer drug Nubeqa™, as well as for Kerendia™, its product for the treatment of chronic kidney disease and heart failure. Nubeqa™ sales advanced by 63.9 percent (Fx & portfolio adj.), mainly driven by volume growth in the United States and Europe, while the 82.9 percent (Fx & portfolio adj.) rise in Kerendia™ sales was largely fueled by higher volumes in the United States and China. The Mirena™ product family also delivered very strong topline performance, especially in the United States, with global sales rising 9.0 percent (Fx & portfolio adj.). In the Radiology business, the division recorded gains of 26.8 and 8.1 percent (Fx & portfolio adj.) for Ultravist™ and CT Fluid Delivery, respectively. Business benefited from higher volumes, while prices remained stable. By contrast, Xarelto™ and Eylea™ sales were down significantly, as anticipated. After encountering headwinds from patent expirations, the oral anticoagulant posted a decline of 42.4 percent (Fx & portfolio adj.), while business with the ophthalmology drug decreased 32.8 percent (Fx & portfolio adj.). The Eylea™ 8 mg formulation offering extended treatment intervals accounted for around 55 percent of overall Eylea™ sales. EBITDA before special items at Pharmaceuticals decreased by 3.6 percent to 1.055 billion euros. The decline in earnings was primarily attributable to the division channeling higher investments toward marketing its growth products Lynkuet™ (for the hormone-free treatment of menopause symptoms), Nubeqa™ and Kerendia™. In addition, the prior-year quarter had benefited from proceeds from the sale of non-core businesses. By contrast, earnings benefited from a reduction in allocations to provisions for the Group-wide short-term incentive (STI) program, as well as an inventory write-back. The EBITDA margin before special items decreased by 0.8 percentage points to 23.7 percent. Consumer Health sales up in almost all categories and regions Following a strong first quarter, sales of self-care products (Consumer Health) increased by 1.5 percent (Fx & portfolio adj.) to 1.445 billion euros. Business was up in almost all categories, with Digestive Health delivering the strongest growth, at 9.4 percent (Fx & portfolio adj.). By contrast, sales in the Allergy & Cold category were down 8.0 percent (Fx & portfolio adj.) due to soft seasonality. Regionally, the division continued to face headwinds from a weak market environment in the United States, while business was up year on year in Europe/Middle East/Africa, Latin America and Asia/Pacific. EBITDA before special items at Consumer Health decreased by 3.6 percent to 319 million euros. The decline in earnings was mainly due to an increase in the cost of goods sold and unfavorable product mix effects. These headwinds were only partially offset by the division’s continuous cost and price management efforts. The EBITDA margin before special items declined by 1.1 percentage points to 22.1 percent.   Group sales and earnings up in first half of the year In the first six months of 2026, Group sales rose by 3.3 percent (Fx & portfolio adj.) to 24.277 billion euros. EBITDA before special items advanced 6.6 percent to 6.597 billion euros, while core earnings per share increased 3.4 percent to 3.66 euros. Currency-adjusted Group outlook confirmed Bayer has affirmed its currency-adjusted Group guidance for full-year 2026 for all metrics except net financial debt, which it now expects to come in lower than originally projected, at 29 to 30 billion euros (previous forecast: 32 to 33 billion euros). The revised guidance for this KPI reflects the already announced agreement with Apollo-managed funds and affiliates. They will obtain a minority, non-controlling stake in a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business in exchange for a €3.0 billion capital contribution. In addition, applying the closing rates as of June 30, 2026, instead of March 31, 2026, results in the following changes: Group sales are now expected to come in at 44.7 to 46.7 billion euros (44.5 to 46.5 billion euros at previous closing rates), and core EPS at 4.20 to 4.70 euros (4.10 to 4.60 euros at previous closing rates). Notes: The following tables contain the key data for the Bayer Group and its divisions for the second quarter and the first six months of 2026. The full Half-Year Financial Report is available online at: www.bayer.com/halfyearreport. There is also a digital version available. The speech given by Bill Anderson and Dr. Judith Hartmann to the media will be available online from around 9 a.m. CEST at: www.bayer.com/speeches Live broadcast of the Media Update from around 9 a.m. CEST and recording available from around 12 p.m. CEST at: www.bayer.com/live-mc Additional information for investors, including presentation charts, and access to the live broadcast of the Investor Video Call (from around 2 p.m. CEST) and recording (from around 6 p.m. CEST) available at: www.bayer.com/live-ic Print-quality photos can be found online at: www.bayer.com/photo-footage You can find FAQ on this topic here. Find more information at www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Monsanto wins landmark Roundup™ case at U.S. Supreme Court 2026-06-25 · Bayer · SaaS, Healthcare, Food & drink, Logistics, Sustainability, Legal, Agriculture https://www.bayer.com/media/en-us/monsanto-wins-landmark-roundup-case-at-us-supreme-court/ Leverkusen, June 25, 2026 – The U.S. Supreme Court issued a 7:2 landmark ruling in the Durnell Roundup™ case on Thursday, affirming that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state-law-based failure-to-warn claims when the U.S. Environmental Protection Agency (EPA) has made a definitive determination on product safety. This decision, which reflects strong support across the ideological spectrum of the Court, helps to bring significant containment to the Roundup™ litigation. Glyphosate remains the most studied crop protection tool in the world and this decision affirms that the EPA’s safety determination is the law of the land, ensuring that companies cannot be punished under a patchwork of state tort laws for complying with federal labeling requirements. “This decision is good for American farmers who help feed the world. It provides the regulatory clarity necessary for innovators like us to develop the agricultural tools that guarantee an affordable food supply,” said Bayer CEO Bill Anderson. "This litigation has enormous costs for the company and has impacted public trust. The decision brings overdue justice on an issue that should have been clarified much earlier. It’s time to put it behind us. Strengthened by this ruling, we continue to pursue our multi-pronged containment strategy, which includes the previously announced class settlement.” The majority opinion states: “Durnell’s state law failure-to-warn claim would require a cancer warning on Roundup’s label — a requirement ‘in addition to’ and ‘different from’ the label required by EPA under FIFRA. FIFRA therefore expressly preempts Durnell’s claim.” Impact of the Ruling The holding in Durnell should result in the dismissal of current warnings-based claims and foreclose future claims based on state-failure-to-warn theories, which make up the vast majority of claims in the litigation to date. In February 2026, along with class counsel, Monsanto announced a proposed U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin lymphoma injuries through a long-term compensation program. Monsanto previously explained that the class settlement and Supreme Court strategies were independently necessary and mutually reinforcing elements of the company’s multi-pronged containment strategy. Together with today’s positive ruling, the class – which has received preliminary approval – will help ensure that Monsanto can significantly contain this litigation. Good for farmers, food security, and American consumers For years, American farmers have operated under a cloud of legal uncertainty created not by science, but by the litigation industry. Glyphosate-based herbicides are a foundation of modern, sustainable agriculture. Their safe and effective use supports food security, keeps production costs affordable, makes no-till, sustainable farm practices possible, and allows farmers to do more with less. This ruling restores the regulatory clarity that the agricultural sector, the broader food supply chain, and American consumers deserve after nearly a decade of well-funded attacks by the plaintiffs’ bar. It also provides an opportunity to restore public trust in the scientific consensus on the safety of glyphosate-based herbicides. The studies reviewed by regulatory authorities on glyphosate’s safety in connection with recent registration reviews are publicly available at www.bayer.com/en/glyphosate-studies Court clarifies law that supports science The EPA has repeatedly and unequivocally determined that glyphosate is not likely to be carcinogenic. Every leading independent regulatory body worldwide that has conducted its own review of glyphosate safety — from the European Food Safety Authority to regulators across Asia and Latin America — has reached the same conclusion. This is not the judgment of any single agency or administration; it is the settled consensus of the world's foremost scientific experts. What has challenged this consensus is not new evidence — instead, it is largely a single, decade-old report from the International Agency for Research on Cancer (IARC) used in courtrooms by plaintiffs’ attorneys, despite the fact that every leading regulator in the world that has examined IARC’s report disagrees with its conclusions. Allowing this outlier report to override the expert determinations of federal regulatory agencies and scientists, despite the express uniformity requirements of federal law, has led to a patchwork of jury-by-jury requirements and uncertainties for manufacturers, farmers, and consumers alike. This decision restores the integrity of the scientific regulatory process and the independence of the experts within it. The long road to this moment This litigation has spanned years, consumed enormous resources, and distracted from what the company does best — promoting Health for all, Hunger for none. Many billions have been directed toward the Roundup™ litigation — money that could have funded the next generation of sustainable crop protection tools, breakthrough therapies, or other advances that farmers, consumers, and patients urgently need. These litigation costs diminish investments in innovation and are borne not just by the company, but by every patient waiting for a new therapy, every farmer waiting for a better tool, and every shareholder whose capital was diverted. Today marks the beginning of a new chapter in Health for all, Hunger for none. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Federal judge remands Monsanto class settlement case back to Missouri State Court 2026-06-17 · Bayer · Healthcare, Sustainability, Legal https://www.bayer.com/media/en-us/federal-judge-remands-monsanto-class-settlement-case--back-to-missouri-state-court/ Leverkusen, June 17, 2026 – On Wednesday, Judge Henry E. Autrey, a federal district court judge in the Eastern District of Missouri, issued a ruling remanding the class settlement case, King v Monsanto, back to Missouri State Court. Monsanto released the following statement in response to the Court’s decision: This decision returns jurisdiction over the class settlement to Missouri Circuit Court where the vast majority of pending claims in the Roundup™ litigation have been filed. This decision brings much needed clarity to all parties and will enable the class approval process to continue to move forward. It also renders the related JPML proceedings moot, as this Court has determined the case belongs in state, rather than federal court. Monsanto remains confident that the class settlement, which is supported by plaintiffs’ counsel representing tens of thousands of potential class members, is fair to all parties and the objections have no merit. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Bayer completes acquisition of Perfuse Therapeutics 2026-06-17 · Bayer · Finance, SaaS, Healthcare, Biotech & pharma, Sustainability, Legal, Internet & apps, Medical devices https://www.bayer.com/media/en-us/bayer-completes-acquisition-of-perfuse-therapeutics/ Berlin, Germany, June 17, 2026 – Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously, Bayer now holds the full rights pertaining to PER-001 intravitreal implant, a first in class, sustained release small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR). This acquisition strengthens Bayer’s pharmaceutical pipeline and strategically fits with Bayer’s strong footprint and expertise in ophthalmology. Under the terms of the agreement, Bayer paid an upfront payment of USD 300 million. The transaction carries a total potential value of up to USD 2.45 billion, comprising of the upfront payment and additional success-based milestone payments. For Bayer, BofA Securities acted as exclusive financial advisor and Baker McKenzie acted as legal counsel. For Perfuse, Centerview Partners LLC acted as exclusive financial advisor and Goodwin Procter LLP acted as legal counsel. About Perfuse Therapeutics Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. About Bayer' Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com/ Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. Contact for media inquiries: Lisa Varrelmann, phone: +49 1746466492 Email: lisa.varrelmann@bayer.com Contact for investor inquiries:' Bayer Investor Relations Team, phone +49 214 30-72704 Email: ir@bayer.com' www.bayer.com/de/investoren/ir-team ———————————————————————————————————————————————————————————— Bayer reports solid start to the year and confirms currency-adjusted Group guidance for 2026 2026-05-12 · Bayer · Finance, Healthcare, Retail, Media, Biotech & pharma, Legal, Marketing & advertising, Agriculture https://www.bayer.com/media/en-us/bayer-reports-solid-start-to-the-year-and-confirms--currency-adjusted-group-guidance-for-2026/ Leverkusen, May 12, 2026 – The Bayer Group has reported a solid performance across all divisions for the first quarter of 2026. “We’re pleased with how our businesses started the year and we’re confirming our currency-adjusted outlook for 2026,” CEO Bill Anderson said when presenting the company’s Quarterly Statement for the first quarter on Tuesday. Commenting on the company’s strategic priorities, he explained that “we continue to advance our plan and we’re dialed in on delivering our commitments in the current year.” Group sales came in at 13.405 billion euros in the first quarter of 2026, up 4.1 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). There was a negative currency effect of 886 million euros (Q1 2025: 55 million euros). EBITDA before special items increased by 9.0 percent to 4.453 billion euros. This figure included a negative currency effect of 321 million euros (Q1 2025: 165 million euros). EBIT rose by 51.8 percent to 3.528 billion euros after net special gains of 324 million euros (Q1 2025: net special charges of 587 million euros) that mainly related to the sale of the global Avelox™ business for 250 million euros. Net income came in at 2.763 billion euros, and was therefore more than two times higher than a year earlier. Core earnings per share climbed 12.9 percent to 2.71 euros, largely driven by the increase in earnings at the Crop Science Division. However, growth was partially held back by a negative currency effect of 0.20 euros (Q1 2025: 0.13 euros). Free cash flow came in at minus 2.320 billion euros (Q1 2025: minus 1.528 billion euros). This was mainly attributable to payments to resolve legal proceedings, which increased as expected and largely related to the PCB and glyphosate litigations. Overall, these payments resulted in a net outflow of 2.002 billion euros (Q1 2025: 66 million euros). Net financial debt as of March 31, 2026, came in at 32.518 billion euros, up 9.0 percent from December 31, 2025, as a result of the negative free cash flow. Compared to March 31, 2025, however, net financial debt was down 5.1 percent. Crop Science posts gains in seed and traits In the agricultural business (Crop Science), sales increased by 6.8 percent (Fx & portfolio adj.) to 7.558 billion euros. Growth was mainly driven by Soybean Seed & Traits, which saw sales double (Fx & portfolio adj.) largely due to the previously announced resolution of a licensing agreement with Corteva in North America, with this effect contributing the equivalent of 448 million euros to the topline. The Soybean Seed & Traits business also benefited from price recovery following the return of the dicamba label in the United States. In addition, the division posted a gain of 7.1 percent (Fx & portfolio adj.) at Corn Seed & Traits that was fueled by higher volumes at the start of season in North America and growth across all other regions as well. By contrast, the crop protection business declined, as expected. At Herbicides, for example, sales were down 10.2 percent (Fx & portfolio adj.) overall, with glyphosate-based products experiencing a 15.1 percent decline (Fx & portfolio adj.). In addition, sales at Fungicides decreased 10.7 percent (Fx & portfolio adj.). EBITDA before special items at Crop Science rose by 17.9 percent to 3.014 billion euros. Strong growth in the Soybean Seed & Traits and Corn Seed & Traits businesses, as well as a decrease in the cost of goods sold due to efficiency programs more than offset the negative currency effect of 277 million euros (Q1 2025: 26 million euros). The EBITDA margin before special items increased by 6.2 percentage points to 39.9 percent, in line with the strategic objectives of the Five-Year Framework announced in 2025. Pharmaceuticals records further significant gains for Nubeqa™ and Kerendia™ Sales of prescription medicines (Pharmaceuticals) came in at 4.249 billion euros, in line with the prior year (Fx & portfolio adj. minus 0.5 percent). The division again registered significant gains for Nubeqa™, the cancer drug, and Kerendia™, for the treatment of chronic kidney disease and heart failure. Nubeqa™ sales advanced 57.1 percent (Fx & portfolio adj.) thanks to higher volumes in the United States and Europe, while Kerendia™ sales were up 84.2 percent (Fx & portfolio adj.) due to volume growth in the United States and China. In addition, the division posted further gains in the Radiology business, which includes products such as Ultravist™ and CT Fluid Delivery, with growth driven by higher volumes. By contrast, sales of the oral anticoagulant Xarelto™ declined substantially as expected, falling 40.4 percent (Fx & portfolio adj.) due to patent expirations, while business with the ophthalmology drug Eylea™ was down 20.5 percent (Fx & portfolio adj.) as a result of competitive pressure from generics. The launch of Eylea™ 8 mg offering extended treatment intervals accounted for around 46 percent of overall Eylea™ sales. EBITDA before special items at Pharmaceuticals declined by 7.5 percent to 1.242 billion euros. The decline in earnings was largely due to an increase in selling expenses that primarily related to the marketing of Lynkuet™ (elinzanetant), Bayer’s non-hormonal treatment for menopause symptoms, as well as Nubeqa™ and Kerendia™. Furthermore, the division made higher investments in its R&D activities. In addition, earnings were diminished by price declines, which were mainly attributable to patent expirations and were only partially offset by higher volumes. There was also a negative currency effect of 77 million euros (Q1 2025: 48 million euros). By contrast, earnings benefited from an increase in income from the sale of non-core businesses as well as lower inventory write-offs. The EBITDA margin before special items declined by 0.3 percentage points to 29.2 percent. Consumer Health reports topline growth (Fx & portfolio adj.) driven by Nutritionals and Dermatology Sales of self-care products (Consumer Health) rose by 5.3 percent (Fx & portfolio adj.) to 1.491 billion euros. The division registered gains (Fx & portfolio adj.) in almost all categories and regions. Performance was driven by the Nutritionals and Dermatology categories, which saw sales rise 12.5 percent and 9.6 percent (Fx & portfolio adj.), respectively. Growth in the Nutritionals category was fueled by very strong performance in the Natsana e-commerce business, along with good topline results for Elevit™ that were partly driven by a product-line extension. The Dermatology category continued to benefit from substantial gains for Bepanthen™ in Europe/Middle East/Africa. However, the division continued to encounter a weak market environment in the United States, along with a soft cold season, that weighed on growth. EBITDA before special items at Consumer Health decreased by 1.5 percent to 337 million euros. Earnings were impacted by a negative currency effect of 31 million euros (Q1 2025: no material currency effects) and higher investments in marketing the division’s innovative products. These effects were largely offset by the increase in sales as well as a one-time gain from the sale of minor, non-strategic brands. The EBITDA margin before special items declined by 0.2 percentage points to 22.6 percent. Currency-adjusted guidance confirmed Commenting on the company’s expectations for the year, CFO Wolfgang Nickl said: “We reiterate our outlook at constant currencies for the full-year 2026, while continuing to monitor the geopolitical dynamics.” Bayer has also prepared its guidance based on closing-day rates. Applying the rates in effect on March 31, 2026, the company now expects sales to come in at 44.5 to 46.5 billion euros (previous forecast: 44 to 46 billion euros), EBITDA before special items at 9.4 to 9.9 billion euros (previous forecast: 9.1 to 9.6 billion euros) and core earnings per share at 4.10 to 4.60 euros (previous forecast: 4.00 to 4.50 euros), with the changes solely reflecting the impact of currency effects. “This is just a point-in-time analysis,” noted Nickl, adding that “we would still expect ongoing volatility around foreign exchange rate developments for the rest of this year.” Notes: The following tables contain the key data for the Bayer Group and its divisions for the first quarter of 2026. The full Quarterly Statement for the first quarter is available online at: www.bayer.com/quarterly-statement. There is also a digital version available. The speech given by Bill Anderson and Wolfgang Nickl to the media will be available online from around 10 a.m. CEST at: www.bayer.com/speeches Live broadcast of the media update from around 10 a.m. CEST and recording available from around 1 p.m. CEST at: www.bayer.com/live-mc Additional information for investors, including presentation charts, and access to the live broadcast of the Investor Video Call (from around 2 p.m. CEST) and recording (from around 6 p.m. CEST) available at: www.bayer.com/live-ic Print-quality photos can be found online at: www.bayer.com/photo-footage Find more information at www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline 2026-05-06 · Bayer · Finance, SaaS, Healthcare, Biotech & pharma, Sustainability, Legal, Internet & apps, Medical devices https://www.bayer.com/media/en-us/bayer-to-acquire-perfuse-therapeutics-to-complement-ophthalmology-pipeline/ Berlin, Germany and San Francisco, California USA, May 6, 2026 – Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR). This represents one of the first potential treatments for Glaucoma and DR being studied for its ability to improve the visual field for Glaucoma patients and to improve contrast sensitivity and reduce ischemia in DR patients. “We are excited by the work of the team at Perfuse Therapeutics and encouraged by the potential of PER-001,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. “With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients.”  “I’m incredibly proud of what the Perfuse team has accomplished and deeply thankful to all our investors and collaborators," said Sevgi Gurkan, MD, Founder and CEO of Perfuse Therapeutics, Inc. "Bayer’s vision aligns closely with ours, and they have the scale and global resources to unlock the full potential of PER-001 to change the trajectory of human blindness. We are very excited to see our mission continue with even greater momentum.” Glaucoma is a progressive optic neuropathy that causes the loss of retinal ganglion cells, resulting in loss of visual fields. It is the leading cause of irreversible vision loss1 affecting ~76-80 million people worldwide (2020) and is projected to affect ~112 million people by 2040 due to population aging.2 Despite its prevalence, there are no approved treatments today, preventing disease progression and blindness independently from the saturated approach of lowering intraocular pressure. There is a high unmet medical need for neuroprotective treatments for patients with Glaucoma. Diabetic Retinopathy (DR) is a microvascular complication of diabetes that damages retinal capillaries, causing ischemia, leakage, and neovascularization affecting about 146 million people globally today. This includes about 25 percent of adults with diabetes and is projected to increase to 160 million people by 2045. Currently, 25 million people have vision‑threatening DR and 1.3 million people are blind.3 Under the terms of the agreement, the transaction carries a total potential value of up to USD 2.45 billion, comprising a USD 300 million upfront payment and additional development, regulatory, and commercial milestone payments based on success criteria. For Bayer, BofA Securities is acting as exclusive financial advisor and Baker McKenzie is acting as legal counsel. For Perfuse, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP is acting as legal counsel. The acquisition is subject to and will become effective after receiving the necessary antitrust clearances and Perfuse stockholder approvals. About PER-001 PER-001 is an investigational small molecule endothelin receptor antagonist being developed for the treatment of ophthalmic diseases. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma, diabetic retinopathy, age-related macular degeneration and retinal vein occlusion. Endothelin is involved in inflammation and cell death through its receptors expressed in retinal vascular and neuroretinal cells. The PER-001 intravitreal implant is a bio-erodible implant administered into the vitreous cavity of the eye using a single-use, 25-gauge applicator and designed to provide a sustained release of PER-001, allowing for a convenient dosing regimen. About Perfuse Therapeutics Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. For more information, visit www.perfusetherapeutics.com and LinkedIn. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. 1 Vision Loss Expert Group of the Global Burden of Disease, 2024, Eye ² Sarkis et al., 2025, Frontiers in Med ³ WHO, 2019, World report on vision Executive Summary Bayer Global Media Contact: Lisa Varrelmann, phone +49 1746466492 Email: lisa.varrelmann@bayer.com Contact for investor inquiries: Bayer Investor Relations Team,  phone +49 214 30-72704 Email: ir@bayer.com www.bayer.com/de/investoren/ir-team Perfuse Therapeutics Media Contact: Perfuse Therapeutics Team Email: info@perfusetherapeutics.com Perfuse Therapeutics investor inquiries: Perfuse Therapeutics Team Email: info@perfusetherapeutics.com ———————————————————————————————————————————————————————————— TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation 2026-04-27 · GSK · Legal https://www.gsk.com/en-gb/media/press-releases/tesaro-a-gsk-subsidiary-provides-update-on-anaptysbio-inc-litigation/ Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio, Inc. against TESARO’s claim for anticipatory breach.